7487
Version 8.0 02Mar2016 Page 1 of 71FRED HUTCHINSON CANCER RESEARCH CENTER
UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE
Previous version: 05/05/2015
Current version:  03/02/2016
Title of Protocol:  The Effect of  Antiangiogenic Therapy with P azopanib Prior to Preoperative 
Chemotherapy for Subjects with Extremity Sof t Tissue Sarcomas: A 
Randomized Study to Evalua te Response by Imaging
Investigator List:
Principal Investigator     Professional Title Phone Number
Darin Davidson, MD Assistant Prof essor of Orthopedics and Sports  Medicine,
University of Washington(206) 543-3690
Co-Principal
Investigator
Robin Jones, MD
Eve Rodler, MD
Co-Investigators
Andrew Shields, MD
Elizabeth Loggers, MD, PhDLee Cranmer, MD, PhDAffiliate Professor of  Medicine,  University of Washington
Affiliate Member, Fred Hutc hinson Cancer Res earch Center
Affiliate Assistant Professor of Medicine, University of WashingtonAffiliate Assistant Member , Fred Hutchinson Cancer 
Research CenterClinical Assistant Professor, University of WashingtonAssistant Professor of Medicine, University of WashingtonAssistant Member, Fred Hutc hinson Cancer Research Center
Associate Professor, University of WashingtonAssociate Member, Fred Hu tchinson Cancer Research 
Center(206) 288-7439
(206)-288-7438
(206) 288-6975
(206) 288-7439
Gabrielle Kane, MDRosa Yeh, Pharm. D.      Seth Pollack, M.D.Associate Professor, Radiati on Oncology, University of 
Washington 
Director, Pharmacokinetics Lab SCCAAffiliate Investigator, FHCRCAssistant Professor, University of WashingtonAssistant Member, Fred Hutc hinson Cancer Research Center(206)-598-7362
(206)288-7396
(206)-667-6629
Biostatistician:
Brenda F. Kurland Associate Member, Fred Hutchinson Cancer Resea rch Center      (206)-667-2804
Research Staff: Phase I Program (206) 288-7551
Emergency Contact: Operator at UWMC (206) 598-6190
7487
Version 8.0 02Mar2016 Page 2 of 71Table of Contents
1.0 INTRODUCTION .............................................................................................................................. 4
2.0 BACKGROUND .................................................. ............................................................................. 4
2.1 Soft Tissue Sarcoma Adjuvant and Neoadjuvant Chemotherapy ... ........................................ 4
2.2 Antiangiogenic Therapy in Sarcoma ........................... ............................................................ 6
2.3 Pazopanib in Sarcoma ............................................................................................................. 6
2.4 Study Agent ‚Äì Pazopanib ..................................... ................................................................... 7
2.5 Dose Rationale ....................................................................................................................... 112.6 Chemotherapy ................................................ ........................................................................ 11
2.7 Imaging Studies to Determine Early Response to Therapy in Soft Tissue Sarcoma ............ 112.8 Risks/Benefits ........................................................................................................................ 12
3.0 STUDY OBJECTIVES ............................................ ......................................................................... 12
3.1 Primary Objectives .......................................... ...................................................................... 12
3.2 Secondary Objectives ........................................ .................................................................... 13
4.0 STUDY DESIGN ................................................ .............................................................................. 13
4.1 Description of Study .............................................................................................................. 134.2 Endpoints ................................................... ............................................................................ 13
4.3 Study Procedures ............................................ ....................................................................... 13
5.0 SUBJECT SELECTION ........................................... ........................................................................ 16
5.1 Inclusion Criteria ................................................................................................................... 165.2 Exclusion Criteria .................................................................................................................. 17
6.0 SUBJECT REGISTRATION ........................................ .................................................................... 20
7.0 TREATMENT PLAN .............................................. ......................................................................... 20
7.1 Agent Administration ............................................................................................................ 217.2       Radiation Therapy ................................... .............................................................................. 25
7.3       Surgery .................................................................................................................................. 267.4 Concomitant Medication a nd Supportive Care Guidelines ................................................... 26
7.5 Duration of Therapy ......................................... .....................................................................28
7.6 Duration of Follow Up ....................................... ................................................................... 28
7.7 Dosing Delays/Dose Modifications ...................................................................................... 297.8 Criteria for Evaluability a nd Removal/Withdrawal from Study .. ......................................... 33
8.0 GUIDELINES FOR ADVERSE EVENT REPORTING ................................................................. 34
8.1 Adverse Event Reporting/Institutional Policy ................ ....................................................... 34
8.2 Study-Specific Adverse Event Capture ........................ ......................................................... 37
9.0 DATA AND SAFETY MONITORING PLAN ............................. ................................................. 37
9.1 Data Monitoring ‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶..379.2 Safety Monitoring ‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶...389.3 Auditing ‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶..38
7487
Version 8.0 02Mar2016 Page 3 of 719.4 Quality Assurance Review ‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶‚Ä¶..38
10.0 STUDY AGENT INFORMATION ..................................... ............................................................38
10.1 Pazopanib ................................................................................................................ ‚Ä¶‚Ä¶‚Ä¶..38
10.2 Ifosfamide .............................................................................................................................. 4310.3 Doxorubicin ................................................ ........................................................................... 44
10.4 Mesna .............................................................................................................................. 4710.5 Pegfilgrastim.............................................. ............................................................................ 48
11.0 ASSESSMENT OF EFFICACY ..................................... ................................................................4 9
11.1 Pharmacodynamic Studies ................................... ..................................................................49
11.2 Pharmacokinetic Studies........................................................................................................ 5011.3 Efficacy Variables ......................................... ........................................................................ 51
11.4 Determining Response to Paz opanib for Continuation on Mainte nance ...............................53
12.0 DATA MANAGEMENT/CONFIDENTIALITY ........................... ................................................ 53
13.0 CORRELATIVE STUDIES ............................................................................................................ 54
14.0 STATISTICAL CONSIDERATIONS .............................................................................................54
14.1    Analysis Plan .......................................... ................................................................................ 54
14.2    Sample Size Justification .............................. .......................................................................... 55
14.3    Protocol Enrollment and S pecial Considerations ......... ........................................................... 55
15.0 RECORDS
15.1 Source Documentation ..............................................................................................................56
15.2 Access..................................................... ...................................................................................56
16.0 TERMINATION OF STUDY ...................................... ................................................................... 57
REFERENCES ..................................................... ................................................................................... 57
APPENDICES
APPENDIX A: Study Activitie s and Treatment Calendar
APPENDIX B: Performance Status Criteria
APPENDIX C: Additional Eligibility Criteria for WomenAPPENDIX D: Drugs Known to be Met abolized by Selected CYP450 Is oenzymes
APPENDIX E:  Drugs Associated with QTc ProlongationAPPENDIX F:  Blood Pressure - Re commendations for Data Collectio n and Event Management
7487
Version 8.0 02Mar2016 Page 4 of 711.0 INTRODUCTION
This document is a clinical re search protocol and the descri bed study will be  conducted in 
compliance with the IRB approved protocol, as sociated Federal regulations and all applicable 
IRB requirements.
This is a randomized study in patie nts with intermediate/high gra de adult soft tissue sarcoma of
the extremity or chest wall wh ich will utilize a n oral angiogenesis inhibitor versus placebo 
followed by neoadjuvant chemother apy. The primary objective is to use FDG-PET to evaluate 
early response to antiangiogenic therapy with pazopanib. This will be correlated with 
pharmacokinetic analysi s of pazopanib. Standard RECIST response  to therapy will be measured 
and compared with FDG-PET results . The study will provide preli minary data on the relative 
contributions of pazopanib and che motherapy with doxorubicin an d ifosfamide as measured by 
changes in SUV by FDG-PET.  Sec ondary objectives include: analyz ing the safety of sequential 
pazopanib and neoadjuvant  chemotherapy; measuring histologic re sponse at the time of surgery 
as a surrogate marker of outcome ; and evaluating tumor and seru m biomarker response. The 
hypothesis is that the additi on of pazopanib to preoperative ch emotherapy with doxorubicin and 
ifosfamide will increase the overa ll response rate which could u ltimately translate into an 
improvement in outcome f or patients with resectable soft tissue  sarcoma. The results of this 
study will inform the design a nd feasibility of a larger trial which would incor porate pazopanib 
as neoadjuvant therapy.FDG-PET will be performed pre-treatment, after pazopanib, and a fter neoadjuvant chemotherapy 
to provide correlativ e, exploratory pharm acodynamic data on the  anti-tumor effect of adding 
antiangiogenic inhibition to chemo therapy. Biomarker studies will also be performed including 
plasma measurement of VEGF and s oluble VEGFR2 (sVEGFR2). Quanti tative enzyme-linked 
immunosorbent assays (ELISA) for VEGF and sVEGFR2 will be performed on plasma and 
tumor extracts. Plasma will als o be collected for micro RNA.
This is a pilot study to test the hypothesis that antiangiogenic  therapy with pazopanib
will enhance the response rate of front line chemotherapy agent s as measured by radiologic 
response and tumor necrosis. This would provide the  rationale to  undertake a larger Phase II 
trial, randomizing patients to neoadjuvant c hemotherapy with or without pazopanib, with 
progression-free and overall survival as end points.
2.0 BACKGROUND
2.1 Soft Tissue Sarcoma Adjuvant and Neoadjuvant Chemotherapy
Soft tissue sarcomas account for  less than 1% of all solid tumo rs in adults. They encompass a 
complex heterogeneous group of tumors likely arising from pluripotential mesenchymal stem cells. Although most patients pres ent with localized disease wh ich allows good local control 
by surgical resection and radi ation, approximately 50% die from  subsequent metastatic 
disease.[1,2]  There is a strong  need to develop new treatments which will improve outcome 
for this group o f patients.
7487
Version 8.0 02Mar2016 Page 5 of 71The role of neoadjuvant and/or a djuvant chemotherapy in adult soft tissue sarcomas is 
controversial.  A 1997 individual  patient meta-analysis publish ed in the Lancet of all 
randomized clinical trial data show ed a significant 10% improve ment in local and distant 
disease free survival at 9.4 years follow-up for patients who r eceived adjuvant chemotherapy 
versus those who underwent surgery alone. The meta-analysis fai led to show a significant 
benefit in terms of overall sur vival[3] but a subgroup analysis suggested that patients with 
extremity sarcomas had a 7% imp rovement in overall survival, wh ich was significant. It is 
possible that the benefits of chemotherapy were underestimated in this meta-analysis since 
patients with low grade lesions who would not be expected to be nefit from chemotherapy 
were included and less than 5% of patients re ceived ifosfamide, which was found to be an 
active agent in soft tissue sarc oma in later studies.  A subsequent Italian Phase III study 
involving 104 patients with high gra de, large (> 5 cm) resectable or recurrent extremity and 
limb girdle sarcomas evaluated a djuvant chemotherapy with epirubicin and ifosfamide versus 
observation.[4]  At 5 years follo w-up there was an absolute ove rall survival benefit of 19% 
favoring the chemotherapy arm w hich was significant. When the study was updated at 90 
months, the intent-to-treat ana lysis no longer showed a statist ically significant overall 
survival benefit.[5]  An updated m eta-analysis which included t he meta-analysis from 1997 
as well as 4 modern studies showe d a significant improvement in  overall survival benefit for 
chemotherapy, with an odds ra tio of 0.56 for anthracycline-ifos famide combination therapy. 
[6]  
The sole randomized trial conduc ted in the neoadjuvant setting showed no survival advantage 
in those patients treated with a doxorubicin/ifos famide based-r egimen versus no 
chemotherapy.[7] However, this tr ial was small and may have bee n underpowered to show a 
survival benefit. In additi on, lower doses of doxorubicin (50 mg/m2) and ifosfamide 
(5/gm/m2) for each cycle were administered, compared to what would now be considered 
optimal dosage of these drugs. There are practical and theore tical advantages to offering neoa djuvant chemotherapy for 
patients with large high-risk ext remity sarcomas.  Neoadjuvant chemotherapy may act in the 
early systemic treatment of mic rometastases and improve outcome  for subgroups of patients. 
In one retrospective study combin ing data from Dana Farber and Memorial Sloan Kettering, 
neoadjuvant chemotherapy wit h doxorubicin and ifosfamide provid ed a disease specific 
survival benefit for patients with tumors larger than 10 cm. [8 ] In some cases neoadjuvant 
chemotherapy can downsize tumo rs and improve resectability. Neo adjuvant chemotherapy 
allows the tumor to be used a s a measure of response in-vivo , by performing imaging studies 
before and after treatment.  Final ly, there is prognostic value  to treatment induced pathologic 
necrosis. A study by Eilber and c olleagues from UCLA utilizing neoadjuvant chemotherapy 
and radiation therapy showed that soft tissue sarcoma patients having 5% or less residual 
viable tumor (at least 95% tumor  necrosis) after therapy at the  time of surgery had a 
significantly lower risk for l ocal recurrence and improved over all survival.[9]
While chemotherapy in adult soft  tissue sarcoma may improve outcome for some patients 
with localized disease, there i s a compelling need to develop b etter control of soft tissue 
sarcoma dissemination by syste mic approaches. Even doxorubicin and ifosfamide, the two 
most active agents in soft tissu e sarcoma, result in frequent tu mor recurrence and progression 
after initial responsiveness.
7487
Version 8.0 02Mar2016 Page 6 of 712.2 Antiangiogenic Therapy in Sarcoma
Angiogenesis, the growth of new vessels from pre-existing vasculature, is essential for tumor 
progression.  Since the time that tumor angiogenesis was initia lly postulated by Folkman in 
1971, several basic and clinical s tudies have shown that the gr owth, invasion and metastatic 
potential of solid tumors is de pendent on angiogenesis.[10-13] In the past two decades, 
inhibitors of angiogenesis have  been developed for clinical use  and recently have shown 
clinical benefit i n combination with che motherapy [14,15] and a s monotherapy in certain 
solid tumors [16-18].
Soft tissue sarcomas express vascular endothelial growth factor (VEGF) which is a key 
mediator of angiogenesis.[19, 20]  In one study of 115 patients  with soft tissue sarcoma, the 
concentration of VEGF in the tumor tissue was found to be an in dependent prognostic factor 
for disease outcome.[21] Tumors associated with local recurrenc e or metastasis in this study 
showed a significantly higher tissue VEGF concentration than those without either. In 
addition, VEGF blood levels in patie nts with soft tissue sarcom as are elevated compared with 
healthy controls and correlate with outcome. [19,22-24]. Other angiogenic factors such as 
platelet-derived gro wth factor (PDGF) are likely involved in th e pathogenesis of soft tissue 
sarcoma.[25] Thus, there is a ra tionale for targeting angiogene sis in soft tissue sarcoma. 
Recent clinical trials have provided preliminary evidence to su pport this scientif ic rationale. 
Sunitinib malate and sorafeni b, both small molecule inhibitors whose targets include VEGF 
receptors and PDGF receptor, have shown activity in several sof t tissue sarcoma subtypes as 
monotherapy in Phase II studies.[26,27]  
2.3 Pazopanib in Sarcoma
Pazopanib is an oral angiogenesis inhibitor that potently inhib its the tyrosine kinase activity 
of VEGF, platelet-derived growt h factor receptor (PDGFR) and c- KIT. [28,29,30]  In 
murine studies, pazopanib inhibited VEGF-induced VEGFR2 phospho rylation, tumor 
angiogenesis and the growth of hum an tumor xenografts. In a Pha se I study, pazopanib was 
well tolerated which prompted further studies.  Recently, pazopa nib gained FDA approval 
for the treatment of patients wit h advanced renal cell carcinom a based on the results of a 
Phase III trial which demonstrat ed that the agent improved prog ression-free survival and 
tumor response compared with placebo in this population of patients.[31]
Promising results of a Phase II study conducted by the European  Organization for the 
Research and Treatment of Cancer  (EORTC) in advanced soft tissue  sarcoma have been 
published.[32]  In this study 142 pa tients with intermediate- or  high-grade disease received 
pazopanib 800 mg orally daily. The  progression-free rate at 12 w eeks was 44% in 
leiomyosarcoma patients, 49% in synovial sarcoma patients, and 39% in other subtypes, 
which compares favorably with hi storical controls treated with second-line chemotherapy.  
The median duration of response was longer than 1 year. The most common toxicities were 
hype
rtension, fatigue, hypopigmentation, and nausea. Mild myelosuppression and liver 
enzyme elevations were encounter ed. In light of the anti-tumor a ctivity demonstrated in this 
trial, a double-blind, placebo-controlled, Phase III trial of pazopanib has been initiated in 
patients with angiogenesis-na√Øve , metastatic soft tissue sarcom a who had progressive disease 
after several lines of treatment . [57] Results showed a signifi cant improvement in median 
7487
Version 8.0 02Mar2016 Page 7 of 71progression-free survival for  pazopanib versus placebo, 12.6 mo nths versus 10.7 months, 
respectively.
Given the scientific r ationale for combini ng conventional chemo therapy with inhibitors of 
the VEGF receptor pathway [33] we are interested to evaluate further the potentia l benefit of 
adding pazopanib to standard front-line cytotoxic agents that h ave activity in sarcoma, 
doxorubicin and ifosfamide.
2.4 Study Agent - Pazopanib
Pazopanib is a potent and selec tive, orally bioa vailable, adeno sine triphosphate competitive, 
small molecule inhibitor of vasc ular endothelial growth factor receptor (VEGFR)-1, -2, and -
3, platelet-derived growth f actor receptor (PDGFR)- ƒÆ-»ïDQGF -KIT tyrosine kinases 
(TKs).[34] In human umbilical ve in endothelial cells (HUVECs), pazopanib inhibited 
VEGF-induced VEGFR-2 phosphorylation and was 3- to 400-fold sele ctive for VEGFRs 
compared to 23 other kinases test ed. Pazopanib showed significan t growth inhibition of a 
variety of human tumor xenograf ts in mice, and also inhibited a ngiogenesis in several 
different models of angiogenesi s.  Because angiogenesis is nece ssary for the growth and 
metastasis of solid tumors, and V EGF is believed to have a pivotal role in this process, 
pazopanib treatment may have broad-spectrum clinical utility.
Mechanism of Action
Pazopanib inhibits VEGFR-1, -2, a nd -3 with concentrations causi ng 50% inhibition (IC 50)
values of 10, 30, and 47 nM, respectively, and inhibits PDGFR- ƒÆ-»ïDQGF -KIT with IC 50
values of 71, 84, and 74 nM, respectively [34,35,36].Preclinical Pharmacology, Toxicology , Pharmacokinetics, and Dru g Metabolism
Refer to the Investigator‚Äôs Brochure 2016.Clinical Experience
Approximately 8600 subjects with cancer have been enrolled in clinical studies of 
pazopanib as of September 2015.  In October 2009, the FDA approved pazopanib tablets for 
the treatment of subjects with adv anced renal cell carcinoma (RC C) and soft tissue sarcoma 
(STS).  In addition, several clini cal studies evaluating pazopa nib in non-small cell lung 
cancer (NSCLC), ovarian cancer , breast cancer, cervical cancer, hepatocellular cancer 
(HCC), multiple myeloma (MM), a nd glioma are in progress or hav e been completed.  
Clinical Efficacy
In a randomized, parallel assignment, double-blind, placebo-controlled study evaluating 
safety, efficacy and PFS of subj ects with soft tissue sarcomas,  statistically significant 
improvements in PFS were observed in the pazopanib arm when com pared with subjects 
taking placebo.  The median PFS in the placebo arm was 7.0 week s and in the pazopanib 
arm was 20.0 weeks with corres ponding HR or 0.35 as assessed by independent radiology 
review.  Soft tissue sarcoma sub- types included in this trial included synovial (48.6%), 
adipocytic (26.3%) and ‚Äúother‚Äù sarcomas (39%). [34]In a randomized, double-blind, place bo-controlled phase III stud y evaluating the efficacy 
and safety of pazopanib monothera py in treatment-naive and cyto kine-pretreated subjects 
7487
Version 8.0 02Mar2016 Page 8 of 71with advanced RCC, the median pr ogression-free-survival (PFS) w as significantly 
prolonged with pazopanib compare d with placebo in the overall s tudy population (9.2 vs. 
4.2 months). The objective respons e rate (RR) was 30% with pazo panib and only 3% with 
placebo [37].  In subjects with ova rian cancer, 31% of subjects experienced a CA-125
response to pazopanib, with a median time to response of 29 day s and median duration of 
response of 113 days (Investigat or‚Äôs Brochure, 2010). In a phase  II trial of subjects with 
early-stage NSCLC, 86% of subjects experienced a reduction in t umor volume after short-
term, preoperative use of pazopanib (~2-6 wee ks) as assessed by  high-resolution CT 
scanning [38].  Interim results from a phase II study of pazopanib in subjects with recurrent 
or metastatic breast invasive breast cancer showed that the cli nical benefit rate was 26% 
[39].  The median TTP was 3.7 months, and 50% of subjects with measurable target lesions 
had some decrease in size.  P FS at 3 and 6 months was 55% and 28%, respectively.  
Preliminary results from a randomized study in subjects with first-line advanced ErbB2-positive advanced or metastatic breast cancer showed that a hig her response rate (36.2% vs. 
22.2%) was observed in subjec ts on combination lapatinib 1000 m g once daily + pazopanib 
400 mg once daily compared to monotherapy lapatanib 1500 mg onc e daily [40].  In a 
randomized phase II study of paz opanib vs. lapatinib vs. the com bination of 
pazopanib/lapatinib in advanced and recurrent cervical cancer, there was a 34% reduction in risk for progression in subjects receiving pazopanib relative t o lapatinib.  The median PFS 
was 17.1 weeks in the lapatini b group and 18.1 weeks in the paz opanib group [41].  Interim 
analysis of data from 26 subject s showed that pazopanib has bot h a favorable tox icity profile 
and promising clinical activity in subjects with advanced and p rogressive differentiated 
thyroid cancers [42].  Five confir med partial responses (PRs) ( 19%) were reported.  
Pazopanib has not shown efficacy  in phase II studies conducted i n MM or glioma.[34]
Safety 
The randomized, phase III study i n STS subjects provided a key comparison of safety with 
pazopanib compared to placebo.[34] The most common AEs reported in ¬ï20% of subjects 
in the pazopanib arm were fatigu e (65%), diarrhea (59%), nausea  (56%), weight decreased 
(51%), hypertension (42%), anorex ia (40%), hair color change (d epigmentation; 39%), and 
vomiting (34%), tumor pain (30%), dysguesia (28%), gastrointest inal pain (24%), headache 
(23%), musculoskeletal pain (23 %), myalgia (23%), and dyspnea ( 20%).  Most of the events 
were grade 1 or 2.  A higher numbe r of grade 3 AEs were reporte d in the pazopanib arm 
(63%) compared with the placebo arm (28%).  The most frequent g rade 3 AEs in the 
pazopanib arm were increased ala nine aminotransferase (ALT), in creased aspartate 
aminotransferase (AST), hypertension, and diarrhea.  The freque ncy of grade 4 and grade 5 
AEs was similar between the pa zopanib and placebo arms:  grade 4 in 7% and 6%, 
respectively; grade 5 in 4% and 3%, respectively.
When pazopanib was compared w ith sunitinib in 1102 subjects (55 4 subjects taking 
pazopanib and 548 subjects taking s unitinib), the frequency of AEs was similar (>99% in 
both).  The safety profiles obser ved between the t reatment arms were different, with greater 
frequency of diarrhea (63% paz opanib, 57% sunitinib) and hypert ension (47% pazopanib, 
41% sunitinib).  Subjects who t ook pazopanib whe n compared with  subjects taking sunitinib 
experienced lower frequency of fatigue, nausea, dysguesia and p almar-plantar 
erythrodysesthesia (PPE) syndro me.  Grade 3 and 4 reported adve rse events were similar 
between treatment arms, adding no comparative risk.  However, grade 3 AEs of increased 
7487
Version 8.0 02Mar2016 Page 9 of 71ALT; increased ASP and headache occurred more frequently in the  pazopanib arm when 
compared with the sunitinib arm.  [34]
A comprehensive review of all completed and ongoing pazopanib c linical trials with a cut-
off date of September 2015, lists 15 most commonly occurring se rious AEs (SAEs).[34]
Vomiting and diarrhea are the most  commonly reported SAEs across all the pazopanib 
studies.  As a consequence of thi s, dehydration is also seen with pazopanib treatment.  For 
most reports, the AEs resolved after supportive treatment such as antiemetics, antidiarrheal 
agents, and IV fluids.  GI perforation is commonly associated w ith VEGF pathway 
inhibitors.  This may manifest a s abdominal pain which is not u ncommon in cancer subjects 
for many reasons.  Of the 42 subj ects in pazopanib trials with SAEs of abdominal pain, only 
three had a documented underlyi ng intestinal perforation.  In July 2006, the DCTD, NCI, 
issued an Action Letter to investigators using pazopanib descri bing the occurrence of bowel 
perforations in subjects on pazopanib clinical trials.7KHPRVWFRPPRQ¬ï$(VOHDGLQ JWRSHUPDQHQWGLVFRQWLQXDWLRQ RIVWXG\GUXJZHUH
increased ALT, increased AST, pr oteinuria, fatigue, and hepatot oxicity.  Of these AEs, 
increased ALT, increased AST a nd proteinuria occurred in a high er proportion of  subjects 
taking pazopanib.Dyspnea is also frequently see n in pazopanib-treated subjects a nd may reflect the underlying 
disease under treatment.  Anemia i s commonly seen in cancer sub jects in association with 
chemotherapy, hemorrhage, or in fection.  The SAEs of pyrexia were attributed to multiple 
causes:  concurrent infections , the underlying malignancy, hepa tic events, other concomitant 
medications, and unknown causes.  Hep atic events are thought to  be on-target tyrosine 
kinase inhibitor (TKI) class eff ects, as hepatic enzyme elevati ons have been seen with other 
agents of this class.  Careful c linical evaluation is, therefor e, warranted in subjects with 
hepatic abnormalities.  Pazopanib is not recommended in subject s with severe hepatic 
impairment (defined as total bilirubin >3 UULN regardless of any level of ALT) as there is 
insufficient data in these subjects. Pneumonia can be a complication of chemotherapy or 
can result from debilitation and a dvanced disease.  Review of t he 33 SAEs showed the 
presence of an underlying cau se other than pazopanib in 19 of the 30 subjects.  Fatigue and 
asthenia are commonly repor ted and have multiple causes.
Hypertension observed with pazopa nib is a known class effect.  There have been 30 SAEs 
of hypertension and 3 SAEs of hyp ertensive crisis in pazopanib clinical trials.  There were 
28 subjects who were effectively treated with antihypertensive medication initiation or dose 
adjustment, while 4 had no such tr eatment.  Although there were  29 SAEs of pleural 
effusion, the body of data does not suggest that any of these c ases were due to pazopanib.  
There have been 24 SAEs of pulmona ry embolism (PE) reported in pazopanib trials.  This is 
of particular relevance since othe r members of this class have been associated with PE and 
other venous throm boembolic events.
In 
addition, there have been repor ts of cardiac and cerebral is chemic events, GI perforation 
or hemorrhage, pulmonary hemorrhag e, cerebrovascular hemorrhage , QT prolongation, and 
Torsades de Pointes in pazopanib clinical trials.
7487
Version 8.0 02Mar2016 Page 10 of 71Laboratory abnormalities
In both treatment arms (placebo vs. pazopanib), most on-therapy  hematology grade shifts 
were Grade 1 or Grade 2.  A higher proportion of subjects in th e pazopanib arm had grade 
shifts for neutrophils, platelet s and WBCs compared with the pl acebo arm. Chemistry grade 
shifts that occurred more freque ntly in the pazopanib arm inclu ded hyperglycemia, 
hyperkalemia, hypoglycemia and hyponatremia.  Transaminase elev ations were also more 
common on pazopanib than placebo.  Thi rteen subjects experience d ALT elevations of 
>8UULN, and of these, 5 subjects ex perienced ALT elevations of >20 UULN.  
Clinical Pharmacokinetics
The oral bioavailability of pazopanib reflects absorption that is limited by solubility above 
doses of 800 mg once daily [34,43] Increases in doses above 800 mg to 2000 mg, in the 
fasted state will not result in i ncreased systemic exposure.  G eometric mean pazopanib t ¬Ω
values ranged from 18.1-52.3 hours.  The mean t ¬Ωwas 30.9 hours in the 800 mg once daily 
group, in phase 2 and 3 trials.  Oral absorption is significant ly enhanced when dosed with 
food; therefore, it is recomme nded to administe r pazopanib on a n empty stomach, at least 1 
hour before or 2 hours after a meal.  Age, body weight, gender, a nd race have no significant 
influence on pazopanib PK.
Potential Drug Interactions
Pazopanib is metabolized primari ly by CYP3A4, and systemic expo sure to pazopanib is 
altered by inhibitors and inducer s of this enzyme.  The concomi tant use of strong CYP3A4
inhibitors should be avoided.  Grape fruit may also increase pla sma concentrations of 
pazopanib and should be avoided.  CYP 3A4 inducers such as rifam picin may decrease 
plasma concentrations; therefore , an alternative concurrent med ication with none or minimal 
enzyme induction should be used.  Concommitant medications that ha ve narrow thera peutic windows and are substrates of 
CYP3A4, CYP2D6 or CYP2C8 shoul d be used with caution.  If possi ble, medications that 
are not substrates for these enzymes and/or do not have narrow therapeutic windows should 
be substituted. Pazopanib is a substrate for P- glycoprotein (P-gp) and BCRP tra nsporters.
Dose Selection
Pharmacodynamic data indicate th at pazopanib, at a monotherapy dose of 800 mg once 
daily, results in effects consis tent with inhibition of the VEG F receptors and angiogenic 
factors.[34]  Concentration-effect  relationships were observed between trough plasma 
pazopanib concentrations and the  development of hypertension as  well as the percent 
change from baseline to the nadi r of soluble VEGFR2 (sVEGFR2), a marker of VEGFR 
inhibition.  Decreases in sVEGFR 2 have been correlated with inc reased clinical benefit in 
RCC with other small molecule TKIs.[44] The trough plasma pazopa nib concentrations 
associated with the EC 50in both concentration-effect rel ationships were similar (15.3 
mcg/mL for hypertension and 21.3 mcg/mL for sVEGFR2). Pazopanib monotherapy has 
been approved as a n 800 mg once daily dose for the treatment of  advanced RCC in the US .
7487
Version 8.0 02Mar2016 Page 11 of 712.5 Dose Rationale
In this study, subjects will r eceive pazopanib 800 mg or placeb o orally daily for 14 days (the 
‚ÄúRun-in‚Äù period) followed by pre operative chemotherapy. Doses wi ll be taken fasting (at 
least one hour before and/or 2 hours after dose).
Subjects who respond to pazopani b during the Run-in period will have the option to 
continue pazopanib 800 mg orally da ily for one year following s urgery and completion of 
any adjuvant chemotherapy. Refer to Section 11.3 for details.
2.6 Chemotherapy
Pre-operative chemotherapy will consist of doxorubicin and ifos famide administered on an 
inpatient basis.  The regime n will consist of doxorubicin 75 mg /m2 administered by 
continuous intravenous infusion ove r 3 days with ifosfamide 2 g m/m2administered 
intravenously over 4 hours daily for 5 days with IV fluid and Me sna, every 21 days for 2 to 
4 cycles, depending on clinical a nd radiologic response.  Patie nts may also receive 2 to 4 
cycles of post-operative chemot herapy, (up to 6 cycles total of  neoadjuvant plus adjuvant 
chemotherapy).
2.7   Imaging Studies to Determine Early Response to Therapy in  Soft Tissue Sarcoma
Chemotherapy may improve the c hance for a cure in patients with  high risk sarcomas 
(intermediate to high grade, > 5 cm), but does not benefit every  patient and is  associated 
with toxicities.[3,4]  Identifyi ng sarcoma patients who are lik ely to benefit from 
neoadjuvant and/or adj uvant systemic treatme nt has been challen ging.  In most current trials 
of anticancer drugs, the objec tive radiographic response of tum or to treatment, as defined by 
the international Response Eval uation Criteria in Solid Tumors (RECIST), is used as a 
surrogate measure for therapeutic benefit.[45]  T he assessment of soft tissue sarcoma 
response to chemotherapy is diffi cult, however, because sarcoma s are heterogeneous tumors 
and consist of varying degrees of  cellularity, fibrous septa, s troma, and necrosis. The 
beneficial effects of a therapy w hich is successful at eradicat ing neoplastic cells may be 
masked by a tumor mass that doe s not shrink or even grows due to necrosis or intratumoral 
hemorrhage.[46]  Standard radiologic response defined by a chan ge in the size of the tumor 
to preoperative chemotherapy has  not correlated consistently with histologic results at 
surgery or with survival.[47-49]FDG-PET: Positron emission tomography (PET) using 18F-fluorodeoxyglucose  (FDG), is a 
tool for evaluation of  treatment response in sarcoma. In neoadj uvant therapy for high grade
localized sarcomas, serial FDG- PET is a sensitive method to asse ss early response to 
therapy; pretreatment standardized uptake value (SUV) and chang e in SUV predict 
outcome.[50,51] Eary and colleagues first used FDG-PET in sarcomas and demonstrated the 
relationship between the quantita tive value of the FDG metaboli c rate of tumor and the 
semi-quantitative measure of tumor uptake, the SUV.[52]  Eary a nd colleagues  showed that 
a higher tumor maximum SUV at diagnosis correlated with a greater risk for disease progression and death from disease in patients with soft tissue  or bone sarcomas.[50]  In a 
later study, Schuetze and colle agues found that the pretreatmen t tumor maximum SUV and 
change in maximum SUV after neoa djuvant chemotherapy independen tly identified 
7487
Version 8.0 02Mar2016 Page 12 of 71sarcoma patients at high risk of t umor recurrence.[51]  Forty-si x patients with high-grade 
localized extremity sarcomas wer e studied. Those with a baselin e tumor maximum SUV of 
6 or greater and less than a 40% de crease in FDG uptake after c hemotherapy were at high 
risk for systemic disease recu rrence, estimated to be 90% at 4 years. In contrast, those 
whose tumors had a 40% or more dec line in the tumor maximum SUV  after chemotherapy, 
were at significantly lower ri sk of recurrent disease and death  following surgery and 
radiation.  Interestingly, in this study the histologic respons e to chemotherapy did not 
correlate with patient outcome.  
In this randomized study subjects will undergo baseline staging  scans including FDG-PET. 
After the 14 day Run-in period of  pazopanib versus placebo, and prior to commencement of 
preoperative chemotherapy, subj ects will undergo repeat FDG-PET. After 2 cycles of 
chemotherapy FDG-PET will be repeated.
If results of this trial can be confirmed in larger trials, the n this could establish that changes
in tumor SUV in response to antia ngiogenic therapy and to chemo therapy may distinguish 
those patients who are likely t o benefit from these systemic th erapies from those who will 
not.
2.8 Risks/Benefits
Subjects will have a 2:1 chance of being randomized to receive pre-operative pazopanib
during a Run-in period. The potentia l benefits include early ass essment of response to 
antiangiogenic therapy and possibl e enhanced tumor cell kill. S ubjects who respond to 
pazopanib during the Ru n-in period (defined in Section 11.3) will have the option to 
continue pazopanib for one year, following surgical resection o f their tumor.   
Antiangiogenic therapy may improve outcome for patients with hi gh risk resectable soft 
tissue sarcoma, but this remain s unproven. Benefits of chemothe rapy include a potential 
improvement in disease free surv ival and overall survival compared to no systemic therapy.  
Risks of the study include side effects associated with pazopan ib and with chemotherapy as 
described in Section 10 .
3.0 STUDY OBJECTIVES
3.1 Primary Objectives
xTo determine the absolute valu es and changes in standardized upt ake values (SUV) 
by FDG PET before and after a  14 day Run-in period of pazopanib versus placebo,
and to compare this to the change in SUV following pre-operativ e chemotherapy. 
xTo evaluate the correlation betw een antiangiogenic activity and pazopanib drug 
exposure.
xTo assess the response rate by RE CIST criteria after the 14 day Run-in period of 
pazopanib versus placebo and compare  this to the response rate f ollowing pre-
operative chemotherapy.
7487
Version 8.0 02Mar2016 Page 13 of 713.2  Secondary Objectives
xTo examine the activity of antia ngiogenic therapy with pazopanib combined with pre-
operative chemotherapy for high r isk extremity soft tissue sarc omas as measured by:        
Histological necrosis at surgery
Change in plasma and tumor biom arker assays of angiogenesis 
xTo evaluate the safety of sequ ential treatment  with pazopanib a nd pre-operative 
chemotherapy with doxorubicin and ifosfamide.
4.0 STUDY DESIGN
4.1  Description of Study
This is a multi-center randomiz ed blinded study with 2:1 randomization of pazopanib versus 
placebo prior to neoadjuvant che motherapy with doxorubicin and i fosfamide for adult soft 
tissue extremity sarcomas.
4.2   Endpoints
4.2.1  Primary Endpoints
xAbsolute values and changes in standardized uptake values (SUV)  of tumors 
measured by FDG-PET pre- and pos t receipt of pazopanib versus placebo, and 
post receipt of 2 cycles of preoperative chemotherapy 
xTumor response by RECIST criteria
xCorrelation of pazopanib trough con centration with the change i n SUV from FDG 
PET and change in RECIS T measurements on MRIs
4.2.2   Secondary Endpoints
xSafety profile
xPathologic response at the time of  surgery as measured by % tum or viability  
xProgression free survival and overall survival 
xChange in plasma and tumor angioge nic biomarker levels pre- and 
postneoadjuvant therapy.
4.3 Study Procedures
The study procedures outlined in Appendix A are discussed in thi s section, with the
exception of Treatment (Section 7) .  Screening will occur with in approximately 14 days prior 
(unless otherwise noted) to the first day of dosing (pazopanib versus placebo, Run-in period, 
Day 1). For procedures performed at Screening and repeated, the later procedure performed 
prior to dosing will serve as a ba seline for clinical assessment .
Informed Consent
Signed informed consent will be obtained from the subject or th e subject's legally acceptable 
representative by the principal investigator or a co-investigat or (the ‚ÄúInvestigator‚Äù) before 
any study-specific procedures are undertaken. 
7487
Version 8.0 02Mar2016 Page 14 of 71The Investigator or his/her representative will explain the natu re of the study to the subject, 
and answer all questions regarding this study. Prior to any stu dy-related screening procedures 
being performed on the subject, the informed consent statement will be reviewed, signed, and 
dated by the subject and by the person who administered the informed consent. A copy of the 
informed consent form will be given to the subject and the origi nal will be placed in the 
subject's research chart.
Research analysis of plasma samp les and surgical tumor tissue w ill be performed once the 
subject has signed and dated th e informed consent, approved by the IRB of record, after the 
nature of the testing has been exp lained and the subject has had  the opportunity to ask 
questions. The informed consent mu s t  b e  s i g n e d b e f o r e  t h e  t e s t i n g  is performed or tumor 
tissue and plasma samples  are used for analysis.
Medical History
The following information will be  collected during the Screenin g Visit:
∆îComplete medical history, incl uding documentation of any clinica lly
significant medical condition
∆îOncology history, including primary cancer diagnosis
o Pathology of primary tumoro Stage of tumor  (locatio n, size, grade and depth)
At each visit, the subject's medical history will be reviewed a nd any changes from baseline 
will be recorded. On Run-in period, Day 1 any changes observed fr om the screening 
assessments, prior to dosing, will be recorded in the subject's medical history. All medication 
(prescription or over-the-counter, including vitamins and/or her bal supplements) will be 
recorded beginning with the Screen ing Visit and continued for th e duration of the study.
Physical Examination
A complete physical examination will be performed at Screening,  i n c l u d i n g  h e i g h t .  A
symptom-directed physical examination including weight will be performed at all other visits 
unless indicated otherwise. Clinically significant physical exa mination findings after the
administration of the first day of dosing will be recorded as ad verse events.
12-lead Electrocardiogram (ECG)
A resting 12-lead ECG will be performed at the Screening Visit, u nless performed for 
standard of care within 14 days. The investigator or a designee will sign and date the ECGs, 
determine if any findings outside normal physiological variation  are clinically significant (in 
consultation with a cardiologist if necessary), and document thi s on the ECG report. ECGs 
will also be performed at the initiation of pazopanib maintenan ce therapy, Cycle 1 Day 1 and 
Cycle 2 Day 2.   
Vital Signs
Vital sign determinations of  heart rate, blood pressure and bod y temperature will be 
measured at all visits unl ess indicated otherwise. 
Pregnancy Test
7487
Version 8.0 02Mar2016 Page 15 of 71For female subjects of childb earing potential, a serum pregnanc y test will be performed at the 
Screening Visit and a urine pr egnancy test will be done at the Run-in period Day 1 visit prior 
to the first dose of pazopanib ve rsus placebo. Subjects consider ed not of childbearing
potential must be documented as being surgically sterile or pos t-menopausal (for at least 1
year). The test results must be r eviewed and determined to be ne gative prior to dosing. If the
urine pregnancy test is positive at Cycle 1 Day 1, it should be  confirmed by a serum
pregnancy test. The test may be repeated at the discretion of t he Investigator at any time
during the study. Should the subj ect become pregnant or suspect she is pregnant while 
participating in this study, she should inform the Investigator i mmediately. The Principal 
Investigator should be notified and will be responsible for con tacting the representative at 
Novartis.
Clinical Laboratory Tests
All subjects will undergo the laboratory assessments outlined in Appendix A . After Cycle 1 
Day 1, clinical laboratory tests should be performed within 72 h ours surrounding the 
scheduled study visit date. Any l aboratory value outside the ref erence range that is 
considered clinically significant by the investigator will be fo llowed as appropriate. 
Clinically significant laboratory values will be recorded as adv erse events if they meet the 
criteria as specified in Section 7.7 .
Tumor Assessments (Radiologic)Baseline staging scans including a positron emission tomograph with a built-in CT 
component (FDG-PET), MRI of the p rimary tumor, and diagnostic CT c hest are required at 
Screening (within approximately  14 days of the Run-in Period, D ay 1). After the 14-day 
Run-in period of pazopanib versus  placebo, and prior to commencement of preoperative 
chemotherapy, subjects will undergo repeat FDG-PET and MRI of the  primary tumor. After 
2 cycles of chemotherapy, FDG- PET and MRI of the primary tumor w ill be repeated.
CT of the chest without contrast will be performed approximatel y every 3 months for the first 
year following surgery and MRI  (or CT) of the  primary site of t he tumor will be performed 
every 6 months. 
ECOG Performance Status
The ECOG performance status wi ll be assessed at Sc reening, Run- in Period Day 1 and Day 1 
of each subsequent cycle, Final Visit, and at the 30-day Follow-u p Visit.  See Appendix B
for ECOG criteria. 
Pharmacokinetic Studies
Trough level (22-24 hrs after pa zopanib dosing): A blood sample  (4 mL K2EDTA purple top 
blood collection tube) will be dra wn to assess the trough plasm a pazopanib concentration 
during the 14 day Run-in period of pazopanib monotherapy, after  completion of adjuvant 
chemotherapy, and every 3 months thereafter until completion of pazopanib maintenance 
therapy. During the Run-in period, the trough level will be dra wn twice during Days 10 
through 14: 1) one trough on any of Days 10-14 and 2) on the da y of the FDG PET after the 
Run-in period, 22-24 hours after the patient‚Äôs last dose of pazopanib versus placebo.  After 
completion of surgery/adjuvant chemotherapy, the trough will be  drawn once during each of 
the following periods: 1) Week 2 (Days 10-15 after restarting p azopanib),  
 Weeks 3-4 after 
7487
Version 8.0 02Mar2016 Page 16 of 71restarting pazopanib, and then every 3 months for 1 year).  If all trough levels are drawn, a 
total of 8 samples are possible in a single subject.
An optional full intensive pharm acokinetic visit will be performed in consenting patients 
during Weeks 2-4 in subjects following surgery/adjuvant chemoth erapy. Blood (4 mL 
K2EDTA purple top blood collec tion tube) will be obtained at th e following timepoints: 
immediately before pazopanib dos ing (within 5 minutes before giving pazopanib on the day 
of PK dosing) and 1, 2, 3, 4, 6, 8 hour timepoints (+/- 10 minute s) , and 24 hrs (range 22 to 
24 hours) after dosing (a total of 8 samples/subject).
Biomarker Studies
Plasma will be collected for measurement of VEGF and soluble VEGFR2 (sVEGFR2) at 
baseline, after the 14 day Run-in period of pazopanib, after co mpletion of neoadjuvant 
chemotherapy and approximately ev ery 3 months thereafter until co mpletion of pazopanib 
maintenance therapy, when indi cated.   Quantitative enzyme-link ed immunosorbent assays 
(ELISA) for VEGF and sVEGFR2 will be performed on plasma and tu mor extracts.
Plasma will also be collected for  micro RNA at baseline, after the 14 day Run-in period of 
pazopanib, following neoadjuvant  chemotherapy and every 3 month s thereafter until 
completion of pazopanib mainten ance therapy, when indicated.
5.0 SUBJECT SELECTION 
5.1 Inclusion Criteria
5.1.a  Histologically or cytolog ically confirmed soft-tissue sa rcoma, excluding alveolar 
and embryonal rhabdomyosarcoma , well- and dedifferentiated adipo cytic 
sarcomas, Ewing‚Äôs, osteosarcoma, or  gastrointestinal stromal tu mor. AJCC (6th
Edition) Stage III or T2a Stage II or Stage IV-treatment naive patients planned for 
resection of the prima ry tumor, with resectable metastatic dise ase.
5.1.b Measurable disease greater  than 5 centimeters in greatest dimension.  Measurable 
lesions are defined as those that  can be accurately measured in at least one 
dimension (longest diameter for  non-nodal lesions and short axi s for nodal lesions 
to be recorded) by chest x-ray, C T scan, MRI or with calipers b y clinical exam.  
All tumor measurements must be recorded in millimeters (or decima l fractions of 
centimeters).  
5.1.c Intermediate or high gra de lesions: 2 or 3 on a scale of 1 -3 or grades 2 to 4 on a 
scale of 1-4.
5.1.d Sarcoma located on upper (includes shoulder) or lower (inc ludes hip) extremities 
or on the body wall.
5.1.e Life expectancy of greater than 6 months.
5.1.f (&2*SHUIRUPDQFHVWDWXV¬î.DUQRIVN\¬ï 0%; see Appendix B ).
7487
Version 8.0 02Mar2016 Page 17 of 715.1.g No prior chemotherapy, radiotherapy, or antiangiogenic the rapy.
5.1.h Age > 18 years
5.1.i No significant organ dysfunction with initial labs:
ANC t1500 /PL
Hgb ¬ïJG/
Platelets t100,000 / PL
Creatinine d1.5 x ULN
Bilirubin d1.5 mg/dL
AST/ALT d1.5 x ULN
PT/INR/PTT within 1.2 X the uppe r limit of normal unless a subject is receiving 
Coumadin and has stable INR whic h is in range for the desired l evel of 
anticoagulation
5.1.j Normal cardiac function: LVEF t50%
5.1.k Blood pressure (BP) no greater than 140 mmHg (systolic) and 90 mmHg 
(diastolic) for eligibility.  I nitiation or adjustment of BP me dication is permitted 
prior to study entry provided that the average of three BP readings on baseline 
assessment prior to enrollme nt is less than 140/90 mmHg.
5.1.l Eligibility of subjects receiving any medications or subst ances known to affect or 
with the potential to affect the  activity or pharmacokinetics o f pazopanib will be 
determined following r eview of their cases by the Principal Inv estigator (see 
Section 7.4 for further information).
5.1.m Women of child-bearing potential and men must agree to use  adequate 
contraception.
5.1.n A female is eligible to enter  and participate in this study  if she is of non-
childbearing potential (i.e., physio logically incapable of becom ing pregnant) or if 
she is of childbearing potential , if she fits the criteria in Appendix C .
5.1.o Ability to understand and the  willingness to sign a writte n informed consent 
document.
5.2. Exclusion Criteria
5.2.a Subjects with known brain metas tases and/or unresectable sar coma.
5.2.b Uncontrolled intercurrent illness including, active seriou s infection, symptomatic 
congestive heart failu re, unstable angina pectoris, cardiac ven tricular arrhythmia 
requiring anti-arrhythmic therapy , serious hepatic impairment, or psychiatric 
illness/social situations that would limit compliance with stud y.
5.2.c Pregnant or lactating women.5.2.d Subjects with no additional active malignancy within the la st 3 years.
7487
Version 8.0 02Mar2016 Page 18 of 715.2.e Subjects receiving other investigational agents.
5.2.f Subjects with a history of a llergic reactions attributed t o compounds of similar 
chemical or biologic composition to pazopanib or other agents u sed in the study.
5.2.g Subjects who have both bilirubin >ULN and AST/ALT >ULN
5.2.h Subjects with a urine protei n/creatinine ratio greater tha n 1.
5.2.i Subjects with a baseline QTc of equal to or greater than 480 msecs or other 
significant ECG abnormalities.
5.2.k Certain medications that act  through the CYP450 system are  specifically 
prohibited in subjects receivin g pazopanib and others should be avoided or 
administered with extreme cau tion and require PI approval.
x Strong inhibitors of CYP3A4 such as ketoconazo le, itraconazole, 
clarithromycin, atazanavir, indi navir, nefazodone , nelfinivir, ritonavir, 
saquinavir, telithromycin, voricona zole may increase pazopanib 
concentrations and are prohibited. Grapefruit juice is also an inhibitor of 
CYP450 and should not be ta ken with pazopanib.
x Strong inducers of CYP3A4 , such as rifampin, may decrease pazopanib 
concentrations, are prohibited .  (See Section 7.2)
x Medications which have narrow th erapeutic windows and are subst rates of 
CYP3A4, CYP2D6, or CYP2C8 should be  avoided and, if necessary, 
administered with caution.  (See Section 7.2)
A list of medications that are specifically prohibited or those  that should be used 
with caution during this trial of pazopanib can be found in Section 7.2.
Comprehensive lists of agents th at could affect pazopanib throu gh the cytochrome 
P450 system can be found in Appendix D .
Pazopanib, 800 mg once daily, ha s no effect on CYP2C9, CYP1A2, or CYP2C19 
in vivo but does in vitro.  Therefore, therapeutic doses  of warfarin, a substrate of 
CYP2C9, and omeprazole, a substr ate of CYP2C19 are permitted.  Caffeine, a 
substrate of CYP1A 2, is also permitted.   
5.2.l Certain medications that are associated with a risk for QT c prolongation and/or 
Torsades de Pointes, although not prohibited, should be avoided  or replaced with 
medications that do not carry the se risks, if possible.  Compre hensive lists of 
agents that that are associate d with a risk for QTc prolongatio n and/or Torsades 
de Pointes can be found in Appendix E .
5.2.m Subjects who require heparin ot her than low-molecular weig ht heparin
7487
Version 8.0 02Mar2016 Page 19 of 715.2.n Subjects with any condition that may impair the ability to  swallow or absorb oral 
medications/investigatio nal product including:
xany lesion, whether induced by tu mor, radiation or other condit ions, which 
makes it difficult to swallow capsules or pills 
xprior surgical procedures affe cting absorption including, but n ot limited to 
major resection of s tomach or small bowel
xactive peptic ulcer diseas e, not on a proton pump inhibitor
xmalabsorption syndrome
5.2.o Subjects with any condition that may increase the risk of gastrointestinal bleeding 
or gastrointestinal perforation, including
xactive peptic ulcer diseas e, not on a proton pump inhibitor
xknown intraluminal metastatic lesions
xinflammatory bowel disease ( e.g., ulcerative colitis, Crohn‚Äôs disease) or 
xother gastrointestinal conditi ons which increase the risk of pe rforation
xhistory of abdominal fistula, ga strointestinal perforation or i ntra-
abdominal abscess within 28 days prior to beginning study treat ment
5.2.p Subjects with any of the fo llowing cardiovascular conditio ns within the past 6 
months
xcerebrovascular accident (CVA) or  transient isc hemic attack (TI A) 
xcardiac arrhythmia
xadmission for unstable angina
xcardiac angioplasty or stenting 
xcoronary artery bypass graft surgery 
xpulmonary embolism, untreated deep venous thrombosis (DVT) or D VT 
which has been treated with therapeutic anticoagulation for les s than 6
weeks
xarterial thrombosis 
xsymptomatic peripheral vascular disease.
xClass III or IV heart failure a s defined by the NYHA functional
classification system. A subject who has a history of Class II h eart failure
and is asymptomatic on treatment  may be considered eligible.
5.2.q History of hemoptysis in excess of 2.5 mL (1/2 teaspoon ) within 8 weeks prior to 
first dose of study drug 
5.2.r History of serious or non -healing wound, ulcer, or bone fr acture.
5.2.s HIV-positive subjects on combination antiretroviral therap y are ineligible because 
of the potential for pharmacokine tic interactions with pazopanib.
5.2.t Subjects with severe hepatic impairment
xBilirubin >3 UULN, regardless of any level of ALT
6.0 SUBJECT REGISTRATION AND RANDOMIZATION
7487
Version 8.0 02Mar2016 Page 20 of 71All subjects will be registered b y the coordinating center (Uni versity of Washington) and entered 
into the Protocol Accrual Track ing System (PATS). Information r egarding the PATS system is 
available at http://www.cancerconsortium.or g/rto/protocol_office/pats/.  A complete, signed 
study consent and HIPAA consent are required for registration.  An Investigator must review 
and sign the eligibility list fo r patients enrolled on the tria l.
This is a double-blinded study.  P atients will be randomized 2: 1 to receive pazopanib versus 
placebo by the SCCA Investigator Drug Supply (IDS) Pharmacy acc ording to a computer 
program from randomization.com.  P hysicians, research study sta ff, and patients w ill be blinded 
from the time of enrollment un til the time of the patient's sur gery, when unblinding will occur. 
7.0 TREATMENT PLAN
TREATMENT PAZOPANIB 
RUN-INACYCLES    
1AND 2BCYCLES 
3AND 4CPRE-
OP RT
DSURGERY
ECYCLES 5
AND 6BPOST-OP RTF
DOXORUBICIN 75MG/M2
CIVI
OVER 3
DAYS ,
EACH 
CYCLE
WEEKS  
3-875MG/M2
CIVI
OVER 3
DAYS ,
EACH 
CYCLE
WEEKS   
9-14WEEKS 
16-212-4WEEKS 
AFTER 
COMPLE -
TION OF 
PRE-
OPERATIVE 
THERAPY75MG/M2
CIVI OVER 3
DAYS ,EACH 
CYCLE
2-4 W EEKS 
AFTER 
SURGERY2-4WEEKS AFTER 
COMPLETION OF 
CHEMO -THERAPY
IFOSFAMIDE 2GM/M2
IV, D AYS 
1-5, EACH 
CYCLE
WEEKS  
3-8
(6-D AY
WASHOUT 
AFTER 
PAZOPAN
-IB2GM/M2
IV, D AYS 
1-5, EACH 
CYCLE
WEEKS  
9-142GM/M2I V ,
DAYS 1-5,
EACH CYCLE
2-4WEEKS 
AFTER 
SURGERY
7487
Version 8.0 02Mar2016 Page 21 of 71TREATMENT PAZOPANIB 
RUN-IN ACYCLES    
1AND 2BCYCLES 
3AND 4CPRE-
OP RT
DSURGERY
ECYCLES 5
AND 6BPOST-OP RTF
MESNAIAFTER 
EACH 
DOSE OF 
IFOSAFTER 
EACH 
DOSE OF 
IFOSAFTER EACH 
DOSE OF IFOS
PAZOPANIB
ORPLACEBO800 MG PO
DAILY ,
WEEKS 1-2
PAZOPANIB  
MAINTEN -
ANCEG1WEEK AFTER 
COMPLETION OF 
CHEMO /RT
(DURATION 52
WEEKS )
A Pazopanib versus placebo run-in 14 days
BChemotherapy cycles every 21 days. Cycle 1 may not commence until a 6 day washout period of pazopanib has occurred.
CCycles 3 and 4 will only be given if there is a response to chemotherapy identified on imaging after cycles 1 and 2.
DPre-operative radiation administration, when given, will consis t of external beam 50 Gy in 25  fractions of 2 Gy/fraction 
over 5 weeks. If the target volume encompasses sensitive struct ures such as bowel or lung, the dose can be reduced to 45 Gy in  
25 fractions of 1.8 Gy without protocol violation.
ESurgery should be planned for 2-4 weeks after completion of pre -operative therapy.  Any planned post surgical adjuvant 
chemotherapy should be initiated only after adequate wound heal ing has been achieved.   Patients who require a delay of 
greater than 10 weeks from the initial surgery due to inadequat e wound healing will be removed from further protocol 
therapy.
FPost-operative radiation administration, when given, will consi st of external beam 50 Gy in 25 fractions of 2 Gy/fraction over 5 
weeks, followed by 10 Gy boost (in 5 fractions) to a reduced, o r boost, volume. For contaminated or close margins, the 
boost dose will be 10 - 16 Gy; for microscopically positive marg ins, 16 - 20 Gy, and for grossly positive margins, 20 ‚Äì 26 
Gy. 
For patients who received pre-operative radiation, but have pos itive surgical margins, 16 ‚Äì 20 Gy (2Gy x 8 - 10 fractions) will be 
given by external beam following any planned adjuvant chemother apy.  
GPazopanib may be resumed 1 week after completion of post-operati ve therapy (chemotherapy +/- radiation) for those randomized 
to the treatment who had a response by imaging, to be continued  for 1 year.  Unblinding occurs during the first post-op visit after 
surgery.
HPEG-Filgrastim should be administered approximately 24-48 hours after completing chemotherapy.  10 days of filgrastim may be 
substituted.
I Mesna will be given at 400 mg/m2.  Post IFOS doses will be at 4 hours and 8 hours (+/- standard clinical dosing windows)
7.1 Agent Administration
7.1.1 Pazopanib Administration
Subjects will be randomized t o receive either pazopanib 800 mg orally daily or 
placebo for 14 days as a Run-in pe riod, prior to beginning neoadjuvant chemotherapy 
with doxorubicin and ifosfamide. Doses of pazopanib/placebo will be taken fasting 
(at least 1 hour prior and/or 2 hours after).
7487
Version 8.0 02Mar2016 Page 22 of 71Subjects deemed to be responders to pazopanib preoperative ther apy (defined in 
Section 11.3), will have the option to receive  one year of therapy with paz opanib 800 
mg orally daily following compl etion of surgery and post-operat ive adjuvant 
treatments. 
Treatment Regimen
Treatment will be administere d on an outpatient basis.  Subjects  receive pazopanib 
versus placebo at a dose of 800 mg/day (four 200-mg tablets or t wo 400 mg tablets;
dose modification will be accomp lished by combining 200-mg tablets as necessary).  
Subjects are instructed to swallow tablets once a day (preferab ly in the morning) on 
an empty stomach, either 1 hour  before or 2 hours after food wi th about 1 cup (240 
mL) water. Tablets should be swallowed whole; they must not be c hewed, broken, or 
crushed.  Treatment continues  until one of the criteria in Section 7.3 applies.
For the subjects who will have intensive pharmacokinetic analys es performed during 
pazopanib maintenance, subjects s hould wait to take the pazopan ib on-site (observed 
dose by study personnel).  Subject s should either wait to eat o n-site (1 hour after 
pazopanib dosing) or make sure to eat at least 2 hours before the planned time of 
pazopanib dosing for that day.
Subjects will be provided with a M edication Diary for pazopanib , instructed in its 
use, and asked to bring the diary with them to each appointment.  A new copy of the 
Medication Diary will be given t o subjects whose dose is reduce d due to AEs. Prior 
to the scheduled study visit , subjects will be reminded to document the exact time of 
pazopanib dosing the day before blood is drawn for measurement of trough 
concentrations.  Subjects will also be reminded not to take the ir morning pazopanib 
dose until after the blood draw for trough concentrations has b een completed.
All prescription and over-the-counter medications as well as alternative medicines 
that have been taken within 4 wee ks prior to the first dose of pazopanib must be fully 
documented in the Case Report Fo rm (CRF; indication, dose infor mation and dates of 
administration).  The Investigator  or a designee must be inform ed as soon as possible 
about any new medication taken from the time of screening until  the end the study;
these new medications will be f ully documented in the CRF (indi cation, dose 
information, and dates of  administration).  
All concomitant medications tak en during the study will be recorded in the CRF with 
indication, dose information, a nd dates of ad ministration.
Precautions/Warnings
Certain drugs which induce or inhi bit cytochrome P450 enzymes a re prohibited.
Medical personnel must refer to t he list of prohibited agents in  Section 7.4 prior 
to administering treatment.
7487
Version 8.0 02Mar2016 Page 23 of 71Certain drugs which are listed as ‚Äúuse with caution‚Äù should be avoided if possible, but 
if necessary, subjects who receive  these medications should be closely monitored for 
AEs.  Medical personnel must refer to t he list of ‚Äúuse with caution‚Äù agents in 
Section 7.4_ prior to ad ministering treatment.
Hypertension is an important A E associated with pazopanib.  Fre quent blood 
pressure (BP) monitoring is important in subjects receiving pazopanib versus 
placebo starting on day 8 and continuing until the subject is o ff study.  Experience to 
date suggests that increases in BP may occur following dosing with pazopanib for a 
number of weeks and that these in creases may occur relatively quickly. Section 7.7
includes specific guidelines on the  management of treatment-eme rgent hypertension.  
Recommendations for hypertension monitoring and management are p resented in 
Appendix F .
QTc prolongation and Torsades de P ointes is a rare but serious adverse event 
associated with pazopanib.  There fore, the following is require d:
xIntensive QTc monitoring.  A baseline ECG is required prior to study
registration, and subjects with QTc ¬ï480 msec are excluded . Repeat 
ECG must be performed during the w eek 2.  After surgery, for those 
subjects continuing on maintenan ce pazopanib, if the QTc interv al at 4 
weeks is ¬ï500 msec, the ECG should be repea ted within 7 days and, if the 
QTc interval remains ¬ï500 msec, the subject sho uld be removed from the 
study.  Additionally, if the QTc interval is increased by 60 ms ec or more 
from baseline but the QTc interva l remains at <500 msec, an ECG  should 
EHUHSHDWHGZLWKLQGD\V,IWKH UHSHDW(&*DJDLQVKRZVD¬ïPVHF
increase in the QTc interval from baseline, consideration should be given 
to removing the subject from the  study or increasing monitoring , after 
discussion with the Principal Investigator.
xSubjects must be quest ioned about family history of prolonged Q Tc, 
personal history of p rolonged QTc, relevan t cardiac disease, an d 
concomitant medications which ar e associated with a high risk of  
causing QTc prolongation prior to study registration .
xConcomitant treatment with drugs  that are associated with a hig h risk 
of causing QTc prolongation should be changed to similar agents  that 
do not pose such a risk, if poss ible, prior to a subject receiving the first 
dose of pazopanib. A comprehensive list of agents that are associated 
with a risk of prolonging the Q Tc interval is provided in Appendix E.  
xPotassium, calcium, phosphate, and magnesium levels must be obtained before admini stration of the first  dose of pazopanib a nd 
frequently thereafter (as described in the Study Calendar, Appen dix 
A).  
7487
Version 8.0 02Mar2016 Page 24 of 71xAbnormalities that occur after enrollment in potassium, calcium , 
phosphate, and magnesium levels should be managed as follows: 
Pazopanib should be he ld and an ECG must be performed for 
K\SRNDOHPLDRUK\SHUNDOHPLD¬ïJUDG HK\SRFDOFHPLDRUK\SHUFDOF HPLD
¬ïJUDGHK\SRSKRVSKDWHPLD¬ïJUDGHK\SRPDJQHVHPL a or 
K\SHUPDJQHVHPLD¬ïJUDGH Grading is according to CTCAE v4.  These 
laboratory values should be corr ected as soon as possible in a manner 
consistent with good medical j udgment.  Pazopanib may be re-
administered when hypokalemia or hyperkalemia is grade 1 or within 
LQVWLWXWLRQDOOLPLWVK\SRFDOFHPLDRUK\SHUFDOFHPLDLV¬îJUDGH 
K\SRSKRVSKDWHPLDLV¬îJUDGH DQGK\SRPDJQHVHPLDRU
h\SHUPDJQHVHPLDLV¬îJUDGH(YH QWKRXJKSD]RSDQLEDGPLQLVWUDWL RQLV
allowed at these lower grades, e very effort should be made to c orrect the 
abnormal lab values to n ormal if possible.  
If an ECG, obtained because of these lab values, reveals an inc rease in the 
QTc to >500 msec or an increase in the QTc by at least 60 msec f rom 
baseline, the ECG shoul d be repeated before re-administration o f 
pazopanib.  If the QTc interva l, on the repeat ECG, is still >5 00 msec, the 
subject should be removed from th e study.  If the QTc, on the r epeat ECG, 
remains increased in the QTc by at least 60 msec from baseline b ut is less 
than 500 msec, consideration shoul d be given to removing the subject 
from the study.
Renal function (creatinine and urinary protein)  should be frequently monitored  as 
suggested by the pathologic changes noted in animal studies and  evidence from 
studies of other antiangiogenic agents.  Specific guidelines fo r management of 
proteinuria and elevated creatinine are presented in Section 7.7.
Hepatic Function monitoring include ALT, AST , GGT, alkaline phosphotase and 
total bilirubin at the following visits:
xat screening; 
xbefore initiation of pa zopanib treatment;
xend of week 2;
xprior to Day 1 of each cycle;
xat post-treatment visit;
xfinal visit;
x30-day follow-up
Periodic monitoring should con tinue monthly if pazopanib monoth erapy is continued. 
Pazopanib is not reco mmended for subjects with severe hepatic i mpairment (defined 
as >3UULN, regardless of any level of ALT).
7.1.2 Chemotherapy Administration
7487
Version 8.0 02Mar2016 Page 25 of 71Pre-operative chemotherapy will consist of doxorubicin and ifos famide administered 
on an inpatient basis. Subjects may  also receive 2 to 4 cycles of  post-operative 
chemotherapy, (up to 6 cycles tota l of neoadjuvant plus adjuvan t chemotherapy).  
Doxorubicin: 75 mg/m2by continuous IV infusion days 1 through 3 of each cycle. 
Ifosfamide: 2.0 g/m2  over 4 hours IV, days 1 through 5 of each cycle.
Mesna: 400 mg/m2IV pre, 4 hours post, and 8 hours post each dose of ifosfamide.
Hydration:   D5W with 100 meq/L sodium acetate, 20 meq/L potass ium acetate, 4 
meq/L magnesium sulfate continuous IV infusion at a rate of 83 mL/hour, begun 
approximately 2 hours prior to che motherapy and discontinued after completion of 
chemotherapy and Mesna. 
Cycle 1 of chemotherapy may only commence after a minimum 6-day  washout 
period of pazopanib.
7.2 Radiation Therapy
Radiation treatment ( XRT) will be administe red using standard of care delivery and 
quality assurance techniques, using mega-voltage photons. Elect rons may be used if 
dosimetrically appropriate, but no other particle therapy such as neutrons or protons may
be used.  Brachytherapy and IORT  may be used for boost volumes to sites of residual 
disease, when appropr iate. Simulation must  be CT-based, using c ontrast if possible, and 
appropriate immobiliz ation devices. Target delineation for preo perative XRT must 
include the GTV, CTV, PTV and orga ns at risk, with identified d ose constraints, and for 
postoperative XRT, delineation mus t include the pre-operative G TV, CTV (i.e., surgical 
bed), PTV and organs a t risk, also with ide ntified dose constra ints. Treatment planning 
must generate dosimetry with no m ore than plus or minus 5% hete rogeneity, while 
sparing an adequate strip of circumferential tissue to allow on going lymphatic drainage, 
and utilizing external beam deliver y techniques, such as IMRT and 3-D conformal 
approaches when necessary, to ach ieve this aim . The use of bolus is at the discretion of 
the radiation oncologist, but is ra rely indicated in the preoper ative setting. 
For preoperative XRT, the pres cribed dose to the PTV should be 50 Gy in 25 fractions of 
2 Gy/fraction over 5 weeks. If the  target volume encompasses se nsitive structures such as 
bowel or lung, the dose can be r educed to 45 Gy in 25 fractions  of 1.8 Gy without 
protocol violation.
For postoperative XRT, the pres cribed dose to the PTV should be  50 Gy in 25 fractions 
of 2 Gy/fraction over 5 weeks, followed by 10 Gy boost (in 5 fr actions) to a reduced 
volume.   For contaminated or clo se margins, the boost dose will  be 10 - 16 Gy; for 
microscopically positive margins, 16 - 20 Gy, and for grossly po sitive margins, 20‚Äì 26
Gy. Verification must include initial and weekly isocenter imaging checks with image 
guidance with cone beam CT as appropriate to the technique, as well as weekly on-
treatment patient review visits. D iode checks and physics revie w must be completed as 
standard procedure.  
7487
Version 8.0 02Mar2016 Page 26 of 71Maintenance pazopanib for those who respond to therapy during t he Run-in period, may 
not commence until one  week following completion of radiation. 
7.3 Surgery
The goal of surgical treatment is to resect the tumor with negati ve margins.  All lesions of 
the trunk and extremitie s will be treated with conservative res ection (minimal wide 
excision) after pre-operative t herapy.  Surgical resection shou ld remove as wide a margin 
of tissue around the tumor as pos sible without compromising fun ction.  If postoperative 
pathology evaluation reveals positive soft-tissue margins other  than bone, nerve, or large 
blood vessels, this margin should be re-resected if possible.  If bone, major blood vessel 
or nerve is microscopically positiv e additional radiation should  be given as noted in the 
protocol.  Resectability will depend upon the judgment of the operating surgeon.  For the
extremities, limb salvage procedure is standard of care if achiev able.  For other anatomic 
areas, it must be the judgment of  the operating surgeon that he /she may reasonably expect 
to obtain negative margins. Ext remity patients who are not rese ctable without amputation 
may be amputated, and should compl ete chemotherapy per protocol .
7.4 Concomitant Medication and Supportive Care Guidelines
7.4.1 Potential Drug Interactions
Pazopanib is primarily metaboliz ed by the human CYP3A4 isoenzyme.  Potent CYP3A4 
inhibitors and inducers are prohibited on the trial.
Medications prohibited during paz opanib therapy that strongly i nhibit CYP3A4 
include (but are not limited to) :
xAntibiotics:  clarithromycin, telithromycin, troleandomycin, er ythromycin
xHIV:  protease inhibitors (ritonavir, indinavir, saquinavir, ne lfinavir, amprenavir,
lopinavir)
xAntifungals:  itraconzaole , ketoconazole, voriconazole
xAntidepressants:  nefazodone
xAntiarrythmics: ditiazem, felodi pine, nicardipine, quinidine, v erapamil
Medications prohibited during paz opanib therapy that strongly in duce CYP3A4 
include (but are not limited to) :
xGlucocorticoids:  cortisone (> 50 mg), hydrocortisone (>40 mg), prednisone (>10 mg), 
methylprednisolone (>8 m g), dexamethasone (>1.5 mg)
xAnticonvulsants:  phenytoin, carba mezepine, phenobarbital, oxca rbazepine
xHIV antivirals: efavirenz, nevirapine
xAntibiotics:  rifampin (rifampic in), rifabutin, rifapentene
xMiscellaneous:  St. John‚Äôs Wort , modafinil, pioglitazone, troglitazone, canertinib, 
erlotinib, lapatinib
Pazopanib is a weak inhibito r of CYP3A4, CYP 2C8, and CYP2D6.  D rugs that have narrow 
therapeutic windows and are substrates for these enzymes should be administered with 
7487
Version 8.0 02Mar2016 Page 27 of 71extreme caution.  Because of pazopanib‚Äôs long ha lf-life, caution should continue to be
exercised for at least 14 days aft er the last dose of pazopanib wh en administering these 
medications.
Medications to use with caution th at are substrates for these en zymes and have narrow 
therapeutic windows medications include (but are not limited to ):
xErgot derivatives:  dihydroergotamine, ergonovine, ergotamine, methylergonovine 
(potential increased risk for deve loping ergot toxicity that in cludes severe vasospasm 
leading to peripheral as well as cerebral ischemia)
xNeuroleptics: pimozide (potential i ncreased risk for QT interval  prolongation, ventricular 
arrhythmia, and sudden death)
xAntiarrhythmics:  bepridil, fleca inide, lidocaine, mexiletine, amiodarone, quinidine, 
propafenone (potential increase d risk for QT interval prolongat ion and Torsade de 
Pointes)
xImmune modulators:  cyclosporine, tacrolimus, sirolimus (potent ial increased risk for 
nephrotoxicity and neurotoxicity)
xMiscellaneous:  quetiapine, risperidone, clozapine, atomoxetine , simvastatin, 
bevacizumab, topotecan, short- acting antacids and PPIs.
Pazopanib can prolong the QTc interval.  Drugs that are generally accepted to have a risk of 
causing Torsades de Pointes ( see Appendix E ) should be discontinued o r replaced with drugs 
that do not carry this risk, if at all possible.  Subjects who receive potential QTc-prolonging 
medications ( see Appendix E ) should be monitored closely. 
Pazopanib may increase bleeding .  Subjects, receiving pazopanib  and anticoagulation, should 
be monitored for bleeding.
Pazopanib may cause decreased glucose.  Subjects, receiving pazo panib and hypoglycemia 
agents, should be monitored for hypoglycemia.
7.4.2 Supportive Care 
Anti-Emetics
Routine use of anti-emetics is  recommended for subjects due to the highly emetogenic nature
of the chemotherapy regimen.  S election of anti- emetics is base d on the institution‚Äôs standard 
and is at the Investigator‚Äôs discretion.  
Prophylactic Antibiotics
Prophylactic antibiotics for prevention of neutropenic fever ma y be used at the discretion of
the Investigator.  Use of proph ylactic antibiotics must be reco rded in the case report forms.
Growth Factors
Administration of growth factor is required after all chemother apy cycles:
PEG-filgrastim 6 mg administered as a subcutaneous injection st arting 24-48 hours after 
completion of chemotherapy (may substitute filgrastim 5 mcg/kg/ day (rounded to nearest vial 
7487
Version 8.0 02Mar2016 Page 28 of 71size) administered as a subcutan eous injection starting 24-48 h ours after completion of 
chemotherapy for 10 days, or until white blood count has recove red after nadir (ANC > 
10,000)
Transfusion of Blood Products
Depending on the particular se tting, red blood cell and platele t transfusions may be 
appropriate, at the Investigat or‚Äôs discretion and with the subj ect‚Äôs consent.
7.5 Duration of Therapy
Treatment should continue until th e end of protocol therapy, de fined as the completion of all 
adjuvant treatments following s urgical resection of the primary  tumor, or until one of the 
following criteria applies:
xDisease progression,
xIntercurrent illness that preve nts further administration of tr eatment,
xUnacceptable adverse events(s),
xGreater than 3-week delay in therapy due to adverse event
xThe subject or legal representativ e requests to withdraw from the  study, or
xChanges in the subject's conditi on render the subject unacceptable for further 
treatment in the judgment  of the Investigator.
7.6 Duration of Follow-Up
When a subject discontinues the study, a Final Visit will be co nducted. All subjects will 
have one Follow-up Visit approxima tely 30 days after the Final Visit. This Follow-up Visit 
does not need to be performed for subjects who have had a Final  Visit conducted ¬ï30 days 
after discontinuation of maint enance pazopanib therapy.
Study visits and evaluations will  be performed in clinic at Scr eening and within 
approximately 72 hours prior to hospital admission for each che motherapy cycle 
(neoadjuvant as well as adjuvant). Assessments will include inte rval history, physical 
examination, blood counts and chemistries. Rad iological assessm ents including FDG-PET
CT, MRI of the primary tumor, and diagnostic CT chest will be perf ormed prior to the 14 day 
Run-in period of pazopanib versus  placebo. After the Run-in per iod, and prior to 
commencement of preoperative ch emotherapy, subjects will undergo  repeat FDG-PET CT 
and MRI of the primary tumor. Aft er 2 cycles of chemotherapy, FD G-PET CT and MRI of 
the primary tumor w ill be repeated. ( Refer to Section 4.3 and Appendix A ). Study 
procedures may be performe d up to approximately 72 hours before  or after the scheduled 
visit date.
Subjects will be evaluated daily  during radiation therapy.  Fol lowing surgery, subjects who 
remain on pazopanib monotherapy will have study visits and evaluations monthly for the one 
year duration of therapy, and f ollow-up visits will be every 3 months for those not on 
pazopanib.  CT of the chest wit hout contrast will be performed every 3 months for the first 
7487
Version 8.0 02Mar2016 Page 29 of 71year following surgery and MRI  (or CT) of the  primary site of t he tumor will be performed 
every 6 months.
Following the Final Visit and/or  30-day Follow-up Visit, follow -up will proceed as described 
in the study calendar (Appendix A) until recurrence or progress ion.  Patients experiencing 
recurrence or progression will be contacted every 4 months for overall survival, unless the patient has withdrawn consen t for the study has ended.
7.7 Dosing Delays/Dos e Modifications
Recommendations for pazopanib dose interruptions/modifications i n case of specific 
treatment-emergent AEs are provi ded in the following sections. 
As a general rule, if dose re duction of pazopanib is necessary, the dose should be reduced 
stepwise by 200 mg at each ste p, and the subject should be moni tored for approximately 10 
to 14 days at each dose level.  If toxicity does not abate duri ng this monitoring time, the IP 
may need to be interrupted and/or  the dose further decreased wi th continued monitoring for 
an additional 10-14 days at each dose level, and so on. 
If the toxicity has abated with reduction of the dose and dose re-escalation is considered safe 
by the Investigator, the pazopani b dose can then be increased st ep-wise back to the pre-event 
dose (in 200 mg increments, after monitoring for 10-14 days at each dose level to ensure that 
toxicity did not recur or worsen). 
General: Pazopanib dosing will be modifie d for adverse events according t o the following 
sections.  Reference the following Dose Level table:
*Patients will be removed from pr otocol treatment if dose reduc tion below this level is 
indicated.
7.7.1 Dose Interruptions/Modifications for S pecific, Non-liver R elated, Toxicities
Recommendations for pazopanib (i nvestigational product, IP) dose 
interruptions/modifications in cas e of specific treatment-emerg ent AEs are provided 
in Table 1.
Table 1 Dose Modification Algorithms for Potential Treatment-Rel ated Adverse Events
AE Terms & Descriptions Dose Modification AlgorithmsDose Level Pazopanib
-2* 400 mg daily
-1 600 mg daily
1 800 mg daily
7487
Version 8.0 02Mar2016 Page 30 of 71AE Terms & Descriptions Dose Modification Algorithms
Hypertension
(A). Asymptomatic and persistent SBP of t140 and 
<170 mmHg, or DBP t90 and <110 mmHg, or a clinically 
significant increase in DBP of 20 mmHg (but still below 110 
mmHg).Step 1. Continue investigational product (IP) at the current dose. 
Step 2. Adjust current or initiate  new antihypertensive medication(s).
Step 3. Titrate antihypertensive m edication(s) during next 2 weeks as 
indicated to achieve well-controlledablood pressure (BP). If BP is not well-
controlled within 2 weeks, consider referral to a specialist and go to 
scenario (B).
(B). Asymptomatic SBP t170 mmHg, or DBP t110 mmHg, 
or failure to achieve well-controlled BP within 2 weeks in scenario (A).Step 1. Consider reducing or interrupting IP, as clinically indicated.
Step 2. Adjust current or initiate new antihypertensive medication(s). 
Step 3. Titrate antihypertensive m edication(s) during next 2 weeks as 
indicated to achieve well-controlled BP. 
Step 4. Once BP is well-controlled, restart IP dose-reduced by 200 mg if 
IP was interrupted.
(C). Symptomatic hypertension or recurring SBP t170
mmHg, or DBP t 110 mmHg, despite modification of 
antihypertensive medication(s)Step 1. Interrupt IP 
Step 2. Adjust current or initiate new antihypertensive medication(s). 
Step 3. Titrate antihypertensive m edication(s) during next 2 weeks as 
indicated to achieve well-controlled BP.  Referral to a specialist for further 
evaluation and follow-up is also recommended.Step 4. Once BP is well-controlled, restart IP dose-reduced by 200 mg.
(D). Refractory hypert ension unresponsive to above 
interventions.Discontinue IP and continue follow-up per protocol.
Prolongation of QTc Interval: If the QTc is prolonged, the ECG should be manually read to ensure accuracy of the reading.  The values 
below refer to manually-read ECGs. Refer to Section 7.1.1 for ECG monitoring
QTc  t480 < 500 msec Continue IP; monitor as clinically indicated.
QTc t500 msec Discontinue IP and continue follow-up per protocol.
Proteinuria
UPC <3 Continue pazopanib at the current dos e; monitor as clinically indicated
UPC ‚â• 3 or 24-h urine protein t3g Step 1. Interrupt IP.
Step 2. Weekly UPC or 24-hr urine pr otein monitoring until UPC is <3 or 
24-hr urine protein is <3 grams.   Then restart pazopanib dose-reduced 
by 200 mg.
Step 3.  If UPC ‚â• 3 or 24-h urine protein t 3g recurs, repeat steps 1 and 2.
Step 4.  If UPC ‚â•3 or 24- hr urine protein ‚â•3 recurs and the pazopanib 
dose can no longer be reduced, discontinue pazopanib and continue 
follow-up per protocol.
Hemorrhage /Bleeding: Investigate and doc ument underlying etiology of the bleeding
Grade 1For hemoptysis, interrupt pazopanib and contact the Novartis Study Physician to discuss 
whether further treatment with pazopanib is appropriate.
7487
Version 8.0 02Mar2016 Page 31 of 71For other Grade I hemorrhage/bleeding events,  continue pazopanib at the current dose; 
monitor as clinically indicated.
Grade 2 Step 1. If pulmonary or GI bleed (other than hemorrhoidal bleeding), discontinue IP and 
continue follow-up per protocol. Otherwise , interrupt IP until the AE resolved to dGrade 1. 
Step 2. Restart IP; consider reducing dose and monitor as clinically indicated. 
Grade 3 or 4, or 
Recurrent tGrade 2 event after dose 
interruption/reduction.Discontinue IP and continue with follow-up per protocol. 
Venous Thrombosis (DVT, PE)
Grade 2 Continue IP at the current dose;  monitor as clinically indicated
Grade 3 Step 1. Interrupt IP. 
Step 2. Initiate and monitor anticoagulation as clinically indicated. 
Step 3. Resume IP at same dose only if all of the following criteria are met: 
x The subject must have been treated with anticoagulant at the desired level of 
anticoagulation for at least one week.
x No Grade 3 or 4 or clinically signific ant Grade 2, hemorrhagic events have occurred 
while on anticoagulation treatment.
Subject should be monitored as clinically indicated during anticoagulation treatment and after 
resuming study treatment. When treating with warfarin, international normalized ratio (INR) 
should be monitored within three to five days after any change in IP dosing (eg, re-initiating, escalating/de-escalating, or discontinuing IP), and then at least weekly until the INR is stable. 
The dose of warfarin (or its derivatives) may need to be adjusted to maintain the desired level of anticoagulation
Grade 4 and/or PE Discontinue IP and continue follow-up per protocol. 
Arterial Thrombosis/Ischemia
Any Grade Discontinue IP and continue follow-up per protocol. 
Thrombocytopenia: Investigate and document underlying cause
Grade 1 or 2 Continue IP with current dose;  monitor as clinically indicated. 
Grade 3 or 4 Step 1. Interrupt IP until toxicity resolves to ‚â§Grade 2.
Step 2. Restart IP dose-reduced by 200 mg and monitor as clinically indicated. 
If no recovery to ‚â§ Grade 2 or rec urrent Grade 3 or 4 thrombocy topenia, discontinue IP and 
follow-up per protocol.
Anemia: No specific dose reduction rules are indicated for anemia unless due to hemorrhage or bleeding as noted above.
Palmar-plantar Erythrodysesthesia Syndrome
7487
Version 8.0 02Mar2016 Page 32 of 71Grade 1
Minimal skin changes or dermatitis 
without pain(erythema, oedema, hyperkeratosis)1. Continue IP at present dose
Grade 2
Skin changes with pain; limiting 
instrumental activities of daily living 
(ADLs) (peeling, blisters, oedema, 
bleed, hyperkeratosis)1. Hold IP 
2. Treat as clinically appropriate
3. Upon resolution to Level 1 or better restart  IP with a dose reduction to 400 mg
4. If recurrent consider a further dos e reduction to 200mg or discontinuation
Grade 3Severe skin changes with pain and 
limiting self care ADLs1. Discontinue IP
Other Clinically Significant Adverse Eventsb
Grade 1 Continue IP; monitor as clinically indicated.
Grade 2 or 3, if clinically significant Step 1. Interrupt IP until toxicity resolves to dGrade 1.
Step 2. Restart IP dose-reduced by 200 mg and monitor as clinically indicated. 
Grade 4 Discontinue IP and continue follow-up per protocol.   
a. Well-controlled BP defined as SBP <140 mmHg and mean DBP <90 mmHg.
b. AEs are graded according to NCI Common Terminology Criteria for Adverse Events v4.0 (NCI CTCAE v4)
Abbreviations: BP, blood pressure; IP, investigational product.
7.7.2 Dose Interruptions/Modif ications for Hepatoxicity
AST, ALT and/or Bilirubin
Isolated AST/ALT elevations between 3X ULN 
and 8X ULNReduce pazopanib dose to 200 mg QD, andmonitor weekly until AST/ALT returns to < 2.5
or baseline
AST/ALT >8 X ULN Hold pazopanib until AST/ALT returns to < 2.5
X ULN or baseline.  
If the potential benefit of  reinitiating pazopanib
treatment is considere d to outweigh the risk for 
hepatotoxicity, then c onsider reintroducing  
pazopanib at a reduced dose of 400 mg once 
daily and measure serum liver tests weekly for 8 weeks only after discussion with the PI.
If AST/ALT elevations  >3 X ULN recur, then 
pazopanib should be perman ently discontinued.
AST/ALT >3 X ULN and concurrent bilirubin
elevations >2 X ULNPermanently discontinue pazopanib.
Mild indirect hyperbilirubinemia, known or 
suspected Gilbert‚Äôs sy ndrome, and elevation in 
AST/ALT >3 X ULNContinue pazopanib, but monitor weekly until AST/ALT returns from >3 X ULN to grade 1 (NCI CTCAE) or baseline.
7487
Version 8.0 02Mar2016 Page 33 of 71Severe hepatic impairmen t, defined as bilirubin >3 
X ULN, regardless of any level ALTPermanently discontinue pazopanib.
7.7.3 Chemotherapy Dos e Modifications
A treatment cycle may not begin unless the patient's absolute neutrophil count (ANC) 
is t1500/PL and platelet count is t 100,000/PL (without transfusion).
Patients who experience Grade 3 or 4 hematologic or non-hematol ogic toxicity that is 
attributable to chemotherapy a nd not to the underlying disease should have 
chemotherapy held until the toxicity UHVROYHVWR¬î*UDGH .Dose modifications for 
doxorubicin and ifosfamide-related toxicity will be based on th e Investigator‚Äôs 
discretion.
Patients who are delayed greater  than 3 weeks due to non-resolu tion of such toxicity 
will be taken off study. 
7.8 Criteria for Evaluability and Re moval/Withdrawal from Treatm ent
Criteria for evalua bility of the Trial
xPatients must have received a total of at least 80% of the inte nded dose of 
doxorubicin, ifosfamide, and pazo panib to be evaluable for the trial. If less
than this amount is received, the patient may remain on the stu dy, but will 
not be evaluated for primary endpoints.
Criteria for stopping therapy:
xSubstantial non-compliance with t he requirements of the study.
xAny adverse event which, in the Investigator‚Äôs opinion, require s termination of 
the study medication.
xDisease progression, unless at the discretion of the Investigat or (in 
collaboration with Novartis) continued treatment with study drug is 
appropriate.
xThe patient would benefit from a dditional radiation therapy bey ond that 
specified in the protocol.
xRequest by the patient or a legal representative/relative to st op the treatment.
xThe patient presents with a beta- HCG test consistent with pregn ancy.  
Pregnancy will be reported along the same timelines as a serious adverse event.
xThe patient uses illicit drugs or ot her substances that may, in  the opinion of the
xInvestigator, have a reasonable chance of contributing to toxic ity or otherwise 
interfering with results.
xThe development of a second malig nancy that requires treatment,  which would 
interfere with this study.
xThe patient is lost to follow-up.
xInterruption in administration of  pazopanib or chemotherapy for  greater than 3-
week delay.
xDevelopment of an intercurrent illness or situation which would, in the 
judgment of the Investigator, aff ect assessments of clinical st atus and study 
endpoints to a significant degree.
7487
Version 8.0 02Mar2016 Page 34 of 71Criteria for study withdrawal:
xStudy closure.
xPatient decision to withdraw from  both study therapy and follow-u p.
The Investigator will make every reasonable effort to keep each  patient in the study unless it is 
in the patient‚Äôs best interest  to discontinue participation.  I f a patient is removed from the study 
or declines further participati on, all End of Treatment evaluat ions should be performed if the 
patient is willing and able to be assessed.  A description of t he reason(s) for withdrawal from 
the study will be recorded on the case report form (CRF).  The Investigator should also ensure 
that all patients are followed up f or survival and recurrence a fter the Final Visit.
Relevant visit data should be entered on the CRF and any unused  study medication will be 
accounted for and returned for all patients partic ipating in th e study, even for a brief period of 
time.  Patients who discontinue following entry will have relevant information completed and 
recorded on the CRF.  All patients who discontinue because of a dverse events or clinically 
significant laboratory abnormalities should be followed up until they recover or stabilize, and the subsequent outcome will be recorded.  If any patient should die during the trial or within 30 days of stopping study treatment, the Investigator will inform the IRB and the Novartis 
representative.  The cause of death should be recorded in detai l, within 24 hours, on a serious 
adverse event (SAE) form and r eported to the IRB and Novartis.
Subjects who are withdrawn from th e study prior to surgery will  be replaced and randomized to 
treatment with pazopa nib versus placebo according to the 2:1 de sign.
8.0 GUIDELINES FOR ADVERSE EVENT REPORTING
8.1 Adverse Event Reportin g/ Institutional Policy
In accordance with institutional policy, all adverse events whi ch in the opinion of the Principal
Investigator are unexpected andrelated or possibly rela ted to the research andserious or suggest 
that the research places researc h participants or others at gre ater risk of physical or psychological 
harm than was previously known o r recognized be reported to the  IRB within 10 calendar days 
of learning of the problem.
Definitions:
Adverse Event : - Any untoward medical occurren ce in a patient or clinical inve stigation subject 
administered a pharmaceutical produc t, medical treatment or pro cedure and which does not 
necessarily have to have a causa l relationship with this treatm ent.  An adverse event can 
therefore be any unfavorable a nd unintended sign (including an abnormal laboratory finding, for 
example), symptom, or disease te mporally associated with the us e of a medicinal product, 
medical treatment or procedure wh ether or not considered relate d to the medicinal product. 
Life-threatening Adverse Event: ‚Äì Any adverse event that places  the patient or subject, in view 
of the Investigator, at immediat e risk of death from the reaction.  
7487
Version 8.0 02Mar2016 Page 35 of 71Unexpected Adverse Event: ‚Äì An adverse event is ‚Äúunexpected ‚Äù when its nature (specificity) , 
severity, or frequency are not  consistent with (a) the known or  foreseeable risk of adverse events 
associated with the research proc edures described in the Protocol-related documents, such as the 
IRB-approved research protocol , informed consent document and o ther relevant sources of 
information such as product la beling and package inserts; and a re also not consistent with (b) the 
characteristics of the subject  population being studied includi ng the expected natural progression 
of any underlying disease, disorder or condition any predisposi ng risk factor profile for the 
adverse event.
Serious Adverse Event (SAE): ‚Äì Any adverse event occurring that results in any of the 
following outcomes:  
¬æ death; 
¬æ a life-threatening adverse event (real risk of dying);
¬æ inpatient hospitalization or pr olongation of existing hospitali zation (for 
reasons other than planned chemo therapy or post-surgical care)
¬æ a persistent or significant disability/incapacity;
¬æ a congenital anomaly;
¬æ requires intervention to prevent  permanent impairment of damage .
Attribution: - The following are definitions f or determining whether an adverse event is related 
to a medical product, t reatment or procedure:
An adverse event is ‚Äú related or possibly related to the research procedures‚Äù if in the 
opinion of the Principal Investigator, it was more likely than not caused by the research 
procedures.Adverse events that are solely caused by an underlying disease , disorder or condition of the 
subject or by other circumstan ces unrelated to either the resea rch or any underlying disease, 
disorder or condition of the subject are not ‚Äúrelated or p ossibly related.‚Äù
If there is any question whether or not an adverse event is rel ated or possibly related, the 
adverse event should be reported.
The Cancer Consortium Expedited Reporting Form should be comple ted for all adverse events 
that meet the expedited reporting requirements.  The AE form sh ould be faxed to the IRO at 
(206) 667-6831.  All available in formation should be submitted.
It is the responsibility of the Principal Investigator and/or a  designated staff member to notify 
Novartis, NIH, and the  FDA of adverse events that meet expedite d reporting (such as Serious 
Adverse Events) as required in the protocol.Also considered serious for  the purposes of this study:
xALT >3.0 x ULN with concomitant  elevation in bilir ubin (defined as total bilirubin <2.0 
x ULN or direct bilirubin 35%) or with hypersensitivity symptom s (e.g., fever, rash) ‚Äì
bilirubin fractionation should be pe rformed in testing availabl e.
xALT >8.0 x ULN without bilirubin e levation (define d as total bi lirubin <2.0 x ULN or 
direct bilirubin 35%) and without hypersensitivity symptoms (e.g ., fever, ra
 sh) ‚Äì bilirubin 
7487
Version 8.0 02Mar2016 Page 36 of 71fractionation should be perform ed if testing available.
Serious Adverse Events
For Open Label Portion of Study:
All SAEs arising during the st udy in subjects exposed to pazopa nib will be reported to Novartis 
using copies of the original C ase Report Form pages and within 24 hours of first becoming aware 
of the event, regardless  of causality assessments.
For Blinded Portion of Study:
Study conduct procedures will be  ensured and in place to allow for the expedited reporting of 
relevant SAEs to the appropriate regulatory authorities, IEC(s)  or IRB(s) as required, during the 
course of the study.
SAEs will be sent to Novartis a s they arise in subjects exposed  to pazobanib using copies of the 
original Case Report Form pages and within 24 hour s of first be coming aware of the event, 
regardless of causality assessments.
Pregnancy Reports
Reports of pregnancy informati on on any female subjects who bec omes pregnant while 
participating in the s tudy and following exposure to the study product will be sent to Novartis
using copies of the original C ase Report Form pages and within two weeks of the pregnancy 
(including premature ter mination of the pregnancy).  
Information on the status of the  mother and child will be repor ted to the coordinating center.  
Generally, follow-up will be re quested by Novartis no longer tha n 8 weeks following the 
estimated delivery date.8.2 Study-Specific Adverse Event Capture
8.2.1 Duration and Grade of  Adverse Event Capture
All grade 3 and 4 adverse events occurring after the subject has  t a k e n  t h e  f i r s t  
dose of study drug until the end of study will be recorded in the  subject‚Äôs case 
record form.
Documentation must be supported by an entry in the subject‚Äôs fi le.  A laboratory 
test abnormality considered clinically relevant, e.g., causing t he subject to 
withdraw from the study, requiring treatment or causing apparen t clinical 
manifestations, or judged releva nt by the Investigator, should be reported as an 
adverse event.  Each grade 3 or 4 event should be described in d etail along with 
start and stop dates, severity, r elationship to investigational  product, action taken 
and outcome.
7487
Version 8.0 02Mar2016 Page 37 of 718.2.2 Adverse Event Grading 
Toxicities will be graded using the NCI Common Terminology Crit eria for 
Adverse Events (CTCAE) (the mo st current versio n available.  Th e scale in its 
entirety can be found at:
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickRe ference_8.5x11.pdf
9.0 DATA AND SAFETY MONITORING PLAN
9.1 Data Monitoring
Data and safety monitoring for the study will be performed by t he Clinical Research Support 
Office of the Fred Hutchinson/University of Washington Cancer Co nsortium (the 
‚ÄúConsortium‚Äù). The purpose of the monitoring is to verify the ac curacy of the study data, assess 
compliance with the protocol a nd with Good Clinical Practice (GCP) regulations, and assure the 
timely and complete reporting of s afety (adverse event) data. To  facilitate the monitoring, 
medical records for subjects enr olled by the University of Washi ngton/Seattle Cancer Care 
Alliance (the coordinating center) and Oregon Health & Science University will be reviewed by
the Clinical Research Support Offi ce. The records will be made a vailable for monitoring by 
study staff.
Monitoring for this study will be  scheduled in accordance with t he Cancer Consortium Data and 
Safety Monitoring Plan. The inte rvals and scope  are detailed in the monitoring plan.
9.2 Safety Monitoring
Investigators will conduct con tinuous review of  data and patien t safety.  Bi-monthly review 
meetings will include Principal I nvestigators and study coordin ators.  Other study staff may be 
included per the PI‚Äôs discretion.  A  summary of the following w ill be presented at each meeting:
xTotal subject accrual
xSignificant toxicities experienced by enrolled subjects
xDose modifications and responses
The Principal Investigators a nd co-Investigators will provide study oversight and will review 
adverse events for trends that indicate a change in the known r isks to the study participant. The
Principal Investigator will m eet with these individuals on a re gular basis to review recently 
acquired data, and adverse even ts. If it is the opinion of any in vestigator that the risks or benefits 
to a patient warrant suspension or termination of study activit y, the recommendation must be 
submitted in writing to the Principal Investigator for safety c ommittee review.  The safety 
committee will include John Thompson, MD, and Bojana Askovich, Ph.D in addition to the 
Principal Investigators and pr imary study staff.  Suspension or termination of study activities 
may also be initiated base d on the bi-monthly review.
9.3 AuditingAll trials conduc ted or coordinated by UW/SCCA are subject to a udit.  Internal audit reports will 
be reviewed at bi-monthly meetings.
9.4 Quality Assurance Review (QAR)
All trials conduc ted or coordinated by UW/SCCA are subject to q uality assurance review (QAR).  
Quality assurance review repor ts will be reviewed at bi-monthly  meetings.
7487
Version 8.0 02Mar2016 Page 38 of 7110.0 STUDY AGENT INFORMATION
10.1 Pazopanib (GW786034) (NSC 737754)
Other Names: Pazopanib HCl, GW786034B (the suffix B denotes the
monohydrochloride salt), Votrient.
Classification: VEGFR tyrosine kinase inhibitor
Mechanism of Action: Pazopanib is a highly potent inhibitor of vascular endothelial
growth factor (VEGF) receptor tyrosine 
kinases (VEGFR1,
VEGFR2, and VEGFR3).  Vascular 
endothelial growth factor
receptor inhibition may block VEGF driven 
angiogenesis and, as 
a consequence, constrain tumor growth. 
Molecular Formula:               C21H23N7O2S-HCl        
M.W.:     474.       
Chemical Name:                        5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-
2-pyrimidinyl]amino]-2-methylbenzenesulfonamide monohydrochloride
Approximate Solubility: The monohydrochloride salt is very slightly soluble in 0.1 M HCl (0.65 mg/mL), and is practically insoluble in pH 7.0 phosphate buffer (0.00005 mg/mL), and in pH 11 piperidine buffer (0.0002 mg/mL). 
How Supplied: GW786034 monohydrochloride is supplied as a series of aqueous film-coated tablets containing 100 mg, 200 mg,
                                                     400 mg, an d 500 mg of the free base:
x 100 mg, round, white to off white, packaged in bottles containing 100 tablets each
x 200 mg, oval-shaped, white, packaged in bottles containing 34 tablets each
x 400 mg, oval-shaped, white, packaged in bottles containing 68 tablets each
x 500 mg, capsule shaped, white  to off white, packaged in 
bottles containing 68 tablets each
Tablet excipients in all tablet sizes include microcrystalline
7487
Version 8.0 02Mar2016 Page 39 of 71cellulose, povidone, sodi um starch glycolate, and 
magnesium stearate.  The film-coat consists of titanium
dioxide, hypromellose, polyethylene glycol, and polysorbate 80. 
Storage: The intact bottles should be stored at controlled room
temperature.
Stability: Stability studies are ongoing.
Route of Administration: Oral pazopanib should be taken on an empty stomacheither 1 hour before or 2 hours af ter meals.  The tablets
should be swallowed whole and cannot be crushed or broken.
Method of Administration: Subjects should fast for 2 hour s before and 1 hour after each 
pazopanib dose. 
Availability : Pazopanib is a commercial pr oduct provided to t he SCCA for 
the study by Novartis.
Expected Adverse Events:
The CTEP Comprehensive Adverse Event and Potential Risks list ( CAEPR) provides a single 
list of reported and/or  potential adverse events (AE) associate d with pazopanib. A subset, the 
Agent Specific Adverse Event List (ASAEL), appears in a separat e column and is identified with
bold and italicized text. This subset of AEs (ASAEL) contains events that are consid ered 
'expected' for expedited reporting purposes only. 
Version 2.2, March 18, 20101
Adverse Events with Possible
Relationship to Pazopanib (GW786034)
(CTCAE 4 Term)
[n= 1019]EXPECTED AEs FOR 
ADEERS REPORTING
Agent Specific Adverse 
Event List
(ASAEL)
Likely (>20%) Less Likely (<= 20%) Rare but Serious (<3%) Expected
CARDIAC DISORDERS
Chest pain Angina
Bradycardia Bradycardia
QT-prolongation
Cardiac dysfunction
Left ventricular systolic 
dysfunction
Myocardial infarction
ENDOCRINE DISORDERS
7487
Version 8.0 02Mar2016 Page 40 of 71Hypothyroidism
Liver Failure
GASTROINTESTINAL DISORDERS
Abdominal pain Abdominal pain
Constipation
Flatulence
Diarrhea Diarrhea
Gastrointestinal fistula2Gastrointestinal fistula2
Gastrointestinal hemorrhage3
Gastrointestinal perforation4Gastrointestinal 
perforation4
Nausea Nausea
Vomiting Vomiting
Dyspepsia
Pancreatitis Pancreatitis
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS
Fatigue Fatigue
Chills/Rigors
Vital organ hemorrhages
Infection
INVESTIGATIONS
Alanine aminotransferase 
increasedAlanine aminotransferase 
increased
Aspartate 
aminotransferase increasedAspartate aminotransferase 
increased
Blood bilirubin increased Blood bilirubin increased
Gamma-glutamyl 
transpeptidase increasedGGT Increased
Electrocardiogram QTc 
interval prolonged 
(accompanied by Torsades de 
pointes)
Lipase increased
Lymphocyte count decreased Leukopenia
Neutrophil count 
decreasedNeutropenia
Platelet count decreased Thrombocytopenia
Serum amylase increased
Weight loss
METABOLISM AND NUTRITION DISORDERS
Anorexia Anorexia
Dehydration Dehydration
Hyperglycemia Hyperglycemia
Hypermagnesemia
7487
Version 8.0 02Mar2016 Page 41 of 71Hypoglycemia Hypoglycemia
Hypomagnesemia
Hypophosphatemia Hypophosphatemia
Weight Loss
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS
Arthralgia Arthralgia
Myalgia
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND 
POLYPS)
Tumor pain
NERVOUS SYSTEM DISORDERS
Dizziness Dizziness
Dysgeusia
Extrapyramidal disorder
Headache Headache
Stroke Aneurysm
Reversible posterior
leukoencephalopathy 
syndrome
RENAL AND URINARY DISORDERS
Hematuria
Proteinuria Proteinuria
Urinary fistula Urinary fistula
REPRODUCTIVE SYSTEM AND BREAST DISORDERS
Female genital tract fistula Female genital tract fistula
Uterine fistula Uterine fistula
Vaginal fistula Vaginal fistula
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS
Cough
Dyspnea
Respiratory hemorrhage5Respiratory hemorrhage5
Oral stomatitis Mouth sores
Dysphonia Hoarseness
Pneumothorax
SKIN AND SUBCUTANEOUS TISSUE DISORDERS
Alopecia Alopecia
Edema in face, hands, ankles, 
feet and/or eyelids
Desquamation
Hemoptysis
Blurred vision Ametropia
Palmar-plantar 
erythrodysesthesia 
syndrome
Rash maculo-papular Rash maculo-papular
Skin hypopigmentation Skin hypopigmentation
VASCULAR DISORDERS
7487
Version 8.0 02Mar2016 Page 42 of 71Hypertension Hypertension
Thromboembolic event 
(venous)6
Thrombotic microangiopathy 
(including thrombotic 
thrombocytopenic purpura 
and hemolytic uremic 
syndrome)
Vital organ hemorrhage
Vascular disorders ‚Äì other 
(arterial thromboembolic 
event)6
1This table will be updated as the toxicity profile of the agent  is revised.  Updates will be distributed to all Principal Inve stigators at the 
time of revision.  The current version can be obtained by conta cting PIO@CTEP.NCI.NIH.GOV .
2Gastrointestinal fistula include s Anal fistula, Colonic fistula , Duodenal fistula, Esophageal f istula, Gastric fistula, Gastro intestinal fistula, 
Ileal fistula, Jejunal fistula, Oral cavity fistula, Pancreatic  fistula, Rectal fistula, and Salivary gland fistula under the
GASTROINTESTINAL DISORDERS SOC.
3Gastrointestinal hemorrhage includes Anal hemorrhage, Cecal hem orrhage, Colonic hemorrhage, Duodenal hemorrhage, Esophageal 
hemorrhage, Esophageal varices hemorrhage, Gastric hemorrhage, Hemorrhoidal hemorrhage, Ileal hemorrhage, Intra-abdominal 
hemorrhage, Jejunal hemorrhage, Lower gastrointestinal hemorrha ge, Oral hemorrhage, Pancreatic hemorrhage, Rectal hemorrhage,
Retroperitoneal hemorrhage, and Upper gastrointestinal hemorrha ge under the GASTROINTESTINAL DISORDERS SOC.
4Gastrointestinal perforation includes Colonic perforation, Duod enal perforation, Esophageal perforation, Gastric perforation, I leal 
perforation, Jejunal perforation, Rectal perforation, and Small  intestinal perforation under the GASTROINTESTINAL DISORDERS SO C.
5Respiratory hemorrhage includes Bronchopulmonary hemorrhage, Ep istaxis, Laryngeal hemorrhage, Mediastinal hemorrhage, Pharynge al 
hemorrhage, and Pleural hemorrhage under the RESPIRATORY, THORA CIC AND MEDIASTINAL DISORDERS SOC.
6These events can result in life-threatening pulmonary, cardiac, cerebral, and other complications.
10.2 Ifosfamide (Isophosphamide, Iphosphamide, Z4942, Ifex¬Æ) NSC #109724 (12200 4)
Source and Pharmacology: Ifosfamide is a structural analogue of cyclophosphamide. 
Ifosfamide requires hepatic microsomal activation (P-450 3A isoe nzymes) for the production of 
the reactive 4-hydroxyoxazaphorin e intermediate which serves as a carrier molecule for the 
ultimate intracellular libera tion of acrolein and phosphoramide mustard which is an active 
bifunctional alkylating species. Acrolein is thought to be the c ause of the hemorrhagic cystitis as 
seen with cyclophosphamide. Ifosfamide demonstrates dose-depende nt pharmacokinetics 
whereby the terminal half-life ranges from 7 to 16 hours at dose s of 1.6-2.4g/m¬≤ to 3.8-5 g/m¬≤, 
respectively. At 1.6-2.4g/m¬≤/d, 12 to 18% of the dose was excreted as unchanged drug in the 
urine, whereas at a 5g/m¬≤ singl e-dose, 61% was excreted in the u rine as the parent drug. 
Evidence also exists to suggest that ifosfamide metabolism is i nducible, with more rapid 
clearance occurring i n the second and later doses when a course  of therapy is given as
fractionated doses over 3 to 5 days. T here is more chloroethyl side chain oxidation of ifosfamide 
(up to 50%) than of cyclophospha mide (<10%), and the degree of s uch metabolism is more 
variable than with cyclophosphamid e. Oxidation of the chloroethy l groups produces 
chloroacetaldehyde, which is thoug ht to be responsible for the n eurotoxicity and renal toxicity 
that have been seen with ifosfamide therapy.
7487
Version 8.0 02Mar2016 Page 43 of 71Formulation and Stability: Available in 1 g and 3 g single  dose vials of lyophilized white  
powder without preservatives. R econstitute with sterile water f or injection or bacteriostatic water 
for injection, 20ml for the 1gm vial or with 60mL for the 3gm v ial to produce a final 
concentration of 50mg/ml ifosfa mide. Although the reconstituted  product is stable for 7 days at 
room temperature and up to 6 week s under refrigeration, the manufacturer recommends 
refrigeration and use within 24 hours to reduce the possibility  of microbial contamination. Store 
unreconstituted vials at room temperature 20¬∞-25¬∞C (68¬∞-77¬∞ F). Pro tect from temperatures 
above 30¬∞C (86¬∞ F). Ifosfamide ma y liquefy at temperatures > 35 ¬∞C.
Guidelines for Administration: Solutions of ifosfamide ma y be diluted further to 
concentrations of 0.6 to 20 mg/ml i n dextrose or saline containi ng solutions. Such admixtures, 
when stored in large volume parenteral glass bottles, Viaflex b ags or PAB bags, are physically 
and chemically stable for 1 wee k at 30¬∞C (86¬∞F) or 6 weeks at 5 ¬∞C (41¬∞F). The manufacturer 
recommends refrigeration and use within 24 hours to reduce the possibility of microbial 
contamination.
Supplier: Commercially available from various manufacturers. 
Pregnancy: Women should avoid becoming pregna nt while on therapy.  Breastf eeding should 
be discontinued during therapy.
Expected adverse events:
Central nervous system: Somnol ence, confusion, hallucinations i n 12% and coma (rare) 
have occurred and are usually reve rsible; usually occur with hi gher doses or in patients with 
reduced renal function; depressi ve psychoses, polyneuropathy. Note: CNS depression can 
be reversed with methylene blue  (50 mg intravenously) and methylene blue is recommended 
for prophylaxis for subsequent dos es if the patient has CNS man ifestations with the first 
dose. 
Dermatologic: Alopecia occurs  in 50% to 83% of patients 2-4 weeks after initiation of 
therapy; may be as high as 100% in combination therapy. Phlebit is, dermatitis, nail ridging, 
skin hyperpigmentation, impaired wound healing.
Gastrointestinal: Nausea a nd vomiting in 58% of patients is dose and schedule related (more 
common with higher doses and after bolus regimens); nausea and vomiting can persist up to 
3 days after therapy; also anor exia, diarrhea, constipation, tr ansient increase in LFTs and 
stomatitis noted. Genitourinary: Hemorrhagic cystitis has been frequently associa ted with the use of 
ifosfamide; a urinalysis prior to each dose should be obtained;  ifosfamide should never be 
administered without a ur oprotective agent (MESNA) ; hematuria has b een reported in 
6% to 92% of patients; renal toxic ity occurs in 6% of patients a nd is manifested as an 
increase in BUN or serum creatin ine and is most likely related to tubular damage; renal 
toxicity, including ARF, may occur more frequently with high-do se ifosfamide; metabolic 
acidosis may occur in up to 31% of patients.
Endocrine & metabolic: SIADH 
7487
Version 8.0 02Mar2016 Page 44 of 71Hematologic: Myelosuppression:  Leukopenia is mild to moderate, thrombocytopenia and 
anemia are rare. However, myelo suppression can be severe when u sed with other 
chemotherapeutic agents or wit h high-dose therapy; be cautious with patients with 
compromised bone marrow reserve 
Respiratory: Nasal stuffiness, pulmonary fibrosis
Cardiovascular: Cardiotoxicity 
Miscellaneous: Immunosuppressi on, sterility, possible secondary  malignancy, allergic
reactions
10.3 Doxorubicin (Adriamycin¬Æ) NSC #123127 (042006)
Source and Pharmacology: An anthracycline antibiotic isolated from cultures of Strepto myces
peucetius. The cytotoxic effe ct of doxorubicin on malignant cells and its toxic effects on various 
organs are thought to be relate d to nucleotide base intercalatio n and cell membrane lipid binding 
activities of doxorubicin. Intercalation inhibits nucleotide re plication and action of DNA and 
RNA polymerases. The interaction of doxorubicin with topoisomera se II to form DNA-cleavable 
complexes appears to be an impor tant mechanism of doxorubicin cy tocidal activity. Doxorubicin 
cellular membrane binding may aff ect a variety of cellular func tions. Enzymatic electron 
reduction of doxorubicin by a vari ety of oxidases, reductases an d dehydrogenases generate 
highly reactive species including the hydroxyl free radical OH‚Ä¢ . Free radical formation has been 
implicated in doxorubicin cardiotox icity by means of Cu (II) an d Fe (III) reduction at the cellular 
level. Cells treated with dox orubicin have been shown to manife st the characteristic morphologic 
changes associated with apoptosis or programmed cell death. Doxo rubicin induced apoptosis 
may be an integral component of t he cellular mechanism of actio n relating to therapeutic effects, 
toxicities, or both. Doxorubicin serum decay pattern is multiph asic. The initial distributive t¬Ω is 
approximately 5 minutes suggestin g rapid tissue uptake of doxor ubicin. The terminal t¬Ω of 20 to 
48 hours reflects a slow eliminatio n from tissues. Steady-state distribution volumes exceed 20 to 
30 L/kg and are indicative of extensive drug uptake into tissues . Plasma clearance i s in the range 
of 8 to 20 ml/min/kg and is predominately by metabolism and biliary excretion. The P450 
Cytochromes which appear to be i nvolved with doxorubicin metabolism are CYP2D6 and
CYP3A4. Approximately 40% of the dose appears in the bile in 5 d ays, while only 5 to 12% of 
the drug and its metabolites appear in the urine during the sam e time period. Binding of
doxorubicin and its major meta bolite, doxorubicinol to plasma p roteins is about 74 to 76% and is 
independent of plasma concentration of doxorubicin.
Formulation and Stability: Doxorubicin is available as red-orange lyophilized powder for 
injection in 10mg, 20mg, 50mg, 150mg vials and a preservative fr ee 2mg/ml solution in 10mg, 
20mg, 50mg, 75mg, 200mg vials. Aqueous  Solution: Store refrigerat ed 2¬∞ to 8¬∞C, (36¬∞ to 46¬∞F). 
Protect from light. Retain in carton until contents are used. Pow der for injection: Store 
unreconstituted vial at room tem perature 15¬∞ to 30¬∞C (59¬∞ to 86 ¬∞F). Retain in carton until 
contents are used. Reconstitute with preservative free normal sa line to a final concentration of 
2mg/ml. After adding the diluen t, the vial should be shaken and  the contents allowed to dissolve.  
The reconstituted solution is stable for 7 days at room tempera ture under normal room light and 
15 days under refrigeration 2¬∞ to 8¬∞C (36¬∞ to 46¬∞F). Protect fro m exposure to sunlight.
7487
Version 8.0 02Mar2016 Page 45 of 71Guidelines for Administration: Administer by IV push; by IV side arm into a running infusion; 
or doxorubicin may be further dilu ted in saline or dextrose cont aining solutions and administered 
by infusion. Protect final preparation from light. Avoid extravasation.
Supplier: Commercially available fr om various manufacturers.
Pregnancy: Women should avoid becoming pregna nt while on therapy.  Breastf eeding should 
be discontinued during therapy.
Expected adverse events:
Hematologic: Hematologic side e ffects have been reported in 60% to 80% of patients and 
they may be profound (depending  entirely on dose). While myelosuppression can affect all 
cell lines, leukopenia is mos t common, appearing in 60% to 75% of all treate d patients. 
Absolute white blood cell count s of less than 1,000/mm3 are not  uncommon after 
recommended therapeutic doses. Severe thrombocytopenia and anemi a may also occur.
Gastrointestinal: Gastrointestinal side effects have included ac ute nausea and vomiting in 
20% to 85% of patients. Stomatitis has been reported in up to 80% of patients, and is dose 
and schedule-related. Ulceration of the esophagus and the colon  (particularly the cecum) 
have also been reported. Anorex ia and diarrhea have been report ed in approximately 15% of 
patients. Rare cases of tongue hyperpigmentation have also been  associated with the use of 
doxorubicin.
Dermatologic: Alopecia, flushes, skin and nail hyperpigmentatio n, oncholysis (nail loss),
photosensitivity, hypersensitivity to irradiated skin.
Extravasation: Infiltration can cause severe inflammation, tissue necrosis, and ulceration.   If 
the drug is infiltrated, consult institutional policy, apply ic e to area, and elevate the limb .   
May require debridement.
Hypersensitivity:  Hypersensitivity reactions have occasionally  been reported, and may 
include fever, chills, urticaria, angioneurotic edema or anaphy laxis.  Local IV site "flares" 
can be confused with extravasa tion, but are probably due to all ergy to this drug. Flare 
reactions were reported in 3% t o 18% of patients, but are now ra re since the vehicle in 
which doxorubicin is carried has c hanged. Flare reactions are c haracterized by erythema, 
appear proximally along the af fected vein, and typically resolv e within 45 minutes. Pain, 
burning and adverse sequelae are in frequent or absent. Extravas ation, on the other hand, 
appears at the injection site and resolves slowly over days to weeks. As opposed to flare 
reactions, pain, burning, and ede ma are common, and adverse sequelae are variable and may
be serious.  Allergic reactions  have also been reported after t he intravesical administration 
of doxorubicin.
Renal: Renal insufficiency has  been associated with doxorubicin -induced hyperuricemia 
(secondary to cell lysis). Anima l data suggest that doxorubicin  may cause glomerular 
basement membrane injury via production of reactive oxygen spec ies. Renal side effects 
have included rare cases of new  or worsened renal insufficiency . A single case of rapidly 
progressive glomerulonephritis w ithout evidence of a secondary cause or immunologic 
mechanism has been reported.
7487
Version 8.0 02Mar2016 Page 46 of 71Ocular: Ocular side effects have  included rare cases of conjunct ivitis, periorbital edema, 
lacrimation, blepharospasm, ke ratitis, and decreased visual acu ity.
Genitourinary: Genitourinary side  effects including rare cases o f bladder contracture have 
been reported.
Musculoskeletal: Muscul oskeletal side effect s have been extremely rare. In one case, 
administration of doxorubicin was associated with a clinically significant flare of ankylosing 
spondylitis.
Cardiac: Anthracycline-induced cardiac toxicity may be manifeste d by early or late events.
Early cardiac toxicity consists mainly of sinus tachycardia and /or ECG abnormalities such 
as non-specific ST-T wave change s, but tachyarrhythmias, bradyc ardia, as well as 
atrioventricular and bundle-bra nch block have also been reporte d.  Although rhythm 
disturbances are common after acu te administration they are rar ely of clinical importance. 
Early effects of anthracyclines also include extremely rare cas es of pericarditis-myocarditis 
(which can affect patients wit h no prior history of cardiac disease and which carries a high 
mortality rate of about 20%),  and l eft ventricular dysfunction  (which may lead to clinically 
significant heart failure in pa tients with limited cardiac rese rve). Isolated cases of 
symptomatic supraventricular t achycardia, heart block, and vent ricular arrhythmias (some 
sudden and fatal) have also been r eported.  Cardiovascular side  effects have included 
congestive heart failure due to the developm ent of left ventricu lar (LV) systolic dysfunction 
in 1% to 2% of patients. Retrospec tive data have shown that the  incidence of clinical heart 
failure in patients with preexistin g LV systolic dysfunction (e jection fraction [LVEF] <
50%), who experienced a decline  of 10% or more in absolute LVEF , and who received at 
least 450 mg/m2 cumulative dose, i s approximately 16%. (Data ha ve shown right 
ventricular septal wall motion may also be affected and that LV  diastolic dysfunction may 
precede the development of doxorubi cin-induced LV systolic dysfunction.).
Secondary Leukemia:  The occurrence of secondary acute myelogen ous leukemia has been 
reported in patients treated with anthracyclines. 
Other: Radiation pneumonitis or es ophagitis may be more likely w ith the combination of 
doxorubicin and XRT than with XRT a lone. Prior cardiac or mediastinal XRT appears to 
portend a higher risk of doxorubicin-induced cardiomyopathy. Ot her side effects of 
doxorubicin have included the pr edisposition of patients who have previously received 
radiation therapy (XRT) to demons trate the so-called "recall" p henomenon
10.4 Mesna (sodium 2-mercaptoethane sulf onate,UCB 3983, Mesnex¬Æ) NSC #1138 91 
(012006)
Source and Pharmacology: Mesna was developed as a prophylactic agent to reduce the ris k of
hemorrhagic cystitis induced by if osfamide. Mesna is rapidly ox idized to its major metabolite, 
mesna disulfide (dimesna). Mesna di sulfide remains in the intrav ascular compartment and is 
rapidly eliminated by the kidneys. In the kidney, the mesna disu lfide is reduced to the free thiol 
compound, mesna, which reacts chemi cally with the urotoxic ifos famide metabolites (acrolein 
and 4-hydroxy-ifosfamide) resu lting in their detoxification. The  first step in th e detoxification 
process is the binding of mesna to 4-hydroxyifosfamide forming a nonurotoxic 4-
7487
Version 8.0 02Mar2016 Page 47 of 71sulfoethylthioifosfamide. Mesna also binds to the double bonds of acrolein and to other urotoxic 
metabolites. In multiple human xenograft or rodent tumor model studies, mesna in combination 
with ifosfamide (at dose ratio s of up to 20-fold as single or m ultiple courses) failed to 
demonstrate interference with a ntitumor efficacy.  After an 800 mg dose the half lives for Mesna 
and DiMesna are 0.36 hours and 1.17 hour s, respectively. Approxi mately 32% and 33% of the 
administered dose was eliminate d in the urine in 24 hours as mes na and dimesna, respectively. 
The majority of the dose recovered was eliminated within 4 hour s. Mesna tablets have an oral 
bioavailability of 45- 79% and a urinary bioavailability which r anged from 45-79% of
intravenously administered mesna . The oral bioavailability is u naffected by food. When 
compared to intravenously admin istered mesna, the intravenous pl us oral dosing regimen 
increases systemic exposures (150% ) and provides more sustained excretion of mesna in the 
urine over a 24-hour period.
Unknown Frequency and Timing : **Fetal toxicities and teratogen ic effects of mesna have not 
been noted in animals fed 10 time s the recommended human doses. T here are however no 
adequate and well controlled studi es in pregnant women. It is not known if mesna or dimesna is 
excreted into human milk.Guidelines for Administration: For IV administration, dilute  to 20 mg/mL with dextrose or 
saline containing solutions. Mes na may be mixed with ifosfamide  or cyclophosphamide. After 
dilution for administration, mesna  is physically and chemically  stable for 24 hours at 25¬∫C 
(77¬∫F).  Carefully expel air in syringes prepacked for use to a void oxidation to dimesna. Mesna
may cause false positive te st for urinary ketones.
Supplier: Commercially available from various manufacturers.
Pregnancy: Women should avoid becoming pregna nt while on therapy.  Breastf eeding should 
be discontinued during therapy.
Expected adverse events: 
Cardiovascular: Hypotension 
Central nervous system: Malaise, headache 
Gastrointestinal: Diarrhea, na usea, vomiting, bad taste in mout h, soft stools 
Neuromuscular & skeletal: Limb pain 
Dermatologic: Skin rash, itching
10.5 Pegfilgrastim (pegylated filgrastim, PEG filgrastim, SD/01, Neulasta¬Æ) (072006)
Source and Pharmacology: Pegfilgrastim is the pegylated form of recombinant methionyl 
human G-CSF (filgrastim). Pegfilgrastim is produced by covalentl y binding a 20-kilodalton (kD) 
monomethoxypolyethylene glycol m olecule to the N-terminal methi onyl residue of filgrastim. 
The molecular weight of pegfilgrastim is 39 kD. G-CSF is a line age specific colony-stimulating 
factor which regulates the pr oduction of neutrophils within the bone marrow and affects 
neutrophil progenitor prolifer ation, differentiation, and selec ted end-cell functional activation 
(including enhanced phagocytic a bility, priming of the cellular  metabolism associated with 
7487
Version 8.0 02Mar2016 Page 48 of 71respiratory burst, antibody dep endent killing, and the increased expression of some functions 
associated with cell surface antigens). After subcutaneous injec tion the eliminati on half-life of 
pegfilgrastim ranges from 15 to 80 hours and the time to peak c oncentration ranges from 24 to 
72 hours. Serum levels are sustai ned in most patients during th e neutropenic period 
postchemotherapy, and begin to dec line after the start of neutr ophil recovery, consistent with 
neutrophil-dependent elimination.
Formulation and Stability: Supplied as a preservative-free solution containing 6 mg (0.6ml ) of
pegfilgrastim (10mg/ml) in a s ingle-dose syringe with 27 g, ¬Ω i nch needle with an UltraSafe¬Æ 
Needle Guard. Store refrigerate d at 2-8¬∫ C (36-46¬∫F) and in the  carton to protect from light. Prior 
to injection, pegfilgrastim may  be allowed to reach room temper ature protected from light for a 
maximum of 48 hours. Avoid freezing.Guidelines for Administration: Pegfilgrastim should not be administered in the period 
between 2 weeks before and 24 hours after chemotherapy. Do not s hake.
Supplier: Commercially available from various manufacturers
Pregnancy: Women should avoid becoming pregna nt while on therapy.  Breastf eeding should 
be discontinued during therapy.
Expected Adverse Events:
Bone pain was the most frequent  adverse event attributable to p egfilgrastim in clinical trials.  
Hypoxia was observed in one patie nt. Toxicities associated with  the parent compound, filgrastim 
include:
Central nervous system: N eutropenic fever, fever.
Dermatologic: Alopecia.
Gastrointestinal: Nausea, vomiting, diarrhea, mucositis, spleno megaly (this occurs more 
commonly in patients with cycli c neutropenia/congenital agranul ocytosis who received S.C. 
injections for a prolonged (>14 days) period of time; ~33% of t hese patients experience 
subclinical splenomegaly; ~3% of  these patients experience clin ical splenomegaly).
Neuromuscular & skeletal: Medu llary bone pain (24% incidence--t his occurs most 
commonly in lower back pain, posterior iliac crest, and sternum  and is controlled with non-
narcotic analges ics), weakness.
Cardiovascular: Chest pain, fluid retention, transient supravent ricular arrhythmia, 
pericarditis.
Central nervous system: Headache.
Dermatologic: Skin rash.
Gastrointestinal: Anorexia, stomatitis, constipation.
Hematologic: Leukocytosis.
Local: Pain at injec tion site, thrombophlebitis.
Respiratory: Dyspnea, cough, sore throat.
Miscellaneous: Anaphylactic reaction .
7487
Version 8.0 02Mar2016 Page 49 of 7111.0 ASSESSMENT OF EFFICACY
Evaluability: In order for a pat ient to be evaluable, 80% of th e intended dose of all three 
drugs must be delivered in the first 2 cycles of chemotherapy.
11.1 Pharmacodynamic Studies
The primary endpoint of the study i s to evaluate the absolute va lues and changes in maximum 
standardized uptake values of tum ors measured by FDG-PET pre- an d post receipt of pazopanib
versus placebo, and post receipt of 2 cycles of preoperative ch emotherapy. This will be 
compared to tumor response by RECIST criteria.
FDG PET
PET imaging will be performed at  baseline, after the 14 day Run-in Period with pazopanib 
versus placebo and after 2 cycles of neoadjuvant chemotherapy.  Imaging studies will be 
performed on the SCCA GE discovery  LS PET/CT imaging device oper ating in a two-
dimensional high-sensitivity  mode with 35 imaging planes per ax ial field of view of 15 cm 
(plane thickness 4.25 mm) and a n in-plane resolution of 4 to 5 mm.
The UW/SCCA will follow FDG-PET protocol consensus recommendatio ns[53] and PET 
Response Criteria in Solid Tumors (PERCIST), version 1.0.[54]
Key elements of PERCIST include  performance of PET scans in a m ethod consistent with the
National Cancer Institute recommendations. Patients will fast for  at least 4‚Äì6 h before 
undergoing scanning, and the measur ed serum glucose level (no cor rection) must be less than 
200 mg/dL. The patients may be on oral hypoglycemics but not on  insulin. A baseline PET scan 
will be obtained at 50‚Äì70 min after  tracer injection. The follow-u p scan should be obtained 
within 15 min (but always 50 min or  later) of the baseline scan . All scans will be performed on 
the same PET scanner with the same injected dose +/- 20% of radioa ctivity. 
Appropriate atte nuation correction along w ith evaluation for proper PET and CT registration of 
the quantitated areas w ill be performed. SUV will be corrected for  lean body 
mass (SUL) and should not be correct ed for serum glucose levels (glucose corrections have been 
variably useful, and errors in glu cometer measurements are well known and may add 
errors). The SUL will be dete rmined for up to 5 tumors (up to 2 per organ) with the most 
intense18F-FDG uptake.  The SUV peak (this is a sphere with a diameter o f approximately 1.2 
cm‚Äîto produce a 1-cm3-volume spheric ROI) centering  around the hottest point in the t umor 
foci will be determined, and the image planes  and coordinates wi ll be noted (SUL peak). This 
SUL peak ROI will typically include the maximal SUL pixel (whic h should also be recorded) but 
is not necessarily centered on the maximal SUL pixel. Automated methods for searching for this 
peak region will be used. Tumor sizes will be noted and should be  2 cm or larger in diameter for 
accurate measurement, though smaller lesions of sufficient 18F-F DG uptake, including those not 
well seen anatomically, can be  assessed. Each baseline (pretrea tment) tumor SUL peak must be 
1.5 x mean liver SUL + 2 SDs of mean S UL. If the liver is diseased,  2.0 x blood-pool 18F-FDG 
activity + 2 SDs in the mediastinum will be used as minimal metabol ically measurable tumor 
activity.[54]
7487
Version 8.0 02Mar2016 Page 50 of 71Serial PET will measure the SUV (SUV lean or SUL) peak for up to 5 target lesions in order to 
assess FDG uptake pre-therapy , after a 14 day Run-in period of p azopanib versus placebo, and 
after 2 cycles of chemotherapy. Analysis of changes in SUV from baseline and after treatment 
with pazopanib versus placebo and t hen again after chemotherapy  will test whether 
antiangiogenic therapy has anti-tumor efficacy as monotherapy a nd if so, what is its relative 
contribution to a decline in tumor  metabolism compared to chemo therapy.
RECIST
The radiographic response of the primary tumor to preoperative therapy will be evaluated.  For 
subjects with stage II (T2a) or III disease, the primary lesion  will serve as the sole target lesion 
and will be recorded and measured at baseline.  RECIST measurem ents will be performed on 
serial MRIs to evaluate th e correlation with FDG-PET.
For patients with stage IV disease, target lesions will be chos en according to RECIST 
procedure. The longest diameter (LD) of the target lesions will  be measured and reported as the 
baseline LD. The baseline LD will be used as reference to furth er characterize the objective 
tumor response of the measurable  dimension of the disease. This will be compared to changes in 
SUV on FDG PET.  Response and progression will be evaluated in this  study  using  the new 
international criteria proposed  by the Response Evaluation Crit eria in Solid Tumors (RECIST) 
Committee.[55] Changes in only the largest diameter (unidimensio nal measurement) of the 
tumor lesions are used in the RECIST 1.1 criteria.
11.2 Pharmacokinetic Studies
Trough level (22-24 hrs after pa zopanib dosing): A blood sample  will be drawn to assess the 
trough plasma pazopanib concentr ation during the 14 day Run-in period of pazopanib 
monotherapy (2 samples), after c ompletion of adjuvant chemother apy (2 samples), and every 3 
months thereafter until comple tion of pazopanib maintenance the rapy (4 samples).  If all trough 
levels are drawn, a total of 8 samples are possible in a single  subject. The trough levels will be 
compared for any differences  over time and will be  correlated w ith the change in SUV from 
FDG PET and with the change in R ECIST measurements on MRIs. 
In subjects consenting to the op tional full intensive pharmacokinetic visit during Weeks 2-4
following surgery/adjuvant che motherapy, blood will be obtained at the following timepoints: 
immediately before pazopanib dosing (within 5 minutes before gi ving pazopanib on the day of 
PK dosing) and 1, 2, 3, 4, 6, 8 hour timepoints (+/- 10 minutes) , and 24 hrs (range 22 to 24 
hours) after dosing (a total of 8 samples/subject).
Pazopanib pharmacokine tic parameters of max imum observed plasma  concentration (Cmax), 
the time to Cmax (peak time, Tma x), the area under the plasma con centration-time curve 
(AUC0-24hr), concentration at th e end of the dosing interval (C tr), oral clearance (CL/F), 
volume of distribution (Vd/F), and half-life (t 1/2) will be determined usin g noncompartmental 
methods. The correlatio n between trough concentrations and AUC will also be evaluated.
11.3 Efficacy Variables
11.3.1 FDG Criteria for Tumor Response
7487
Version 8.0 02Mar2016 Page 51 of 71Determination of SUV (SUV lean or  SUL) of the primary tumor and metastases will be 
performed, for up up to 5 target lesions, and for non-target le sions.  FDG changes of 
more than 25% from baseline cannot be attributed to the impreci sion of the technique and 
are therefore regarded as true c hanges in tumor glucose metabol ism.[54] FDG criteria for 
tumor response will be as per th e PET Response Criteria in Solid Tumors (PERCIST) 
criteria.[54] PERCIST includes a specific percentage reduction i n the SUV (SUV lean, 
or SUL) from baseline.  Response to therapy is assessed as a co ntinuous variable and 
expressed as percentage change in SUL peak (or sum of lesion SU Ls) between the pre-
and post treatment scans.  A complete metabolic response is def ined as visual 
disappearance of all metabolically active tumor. A partial resp onse is considered more 
than a 30% and a 0.8-unit decline in SUL peak between the most intense lesion before 
treatment and the most intense lesion  after treatment, althoug h not necessarily the same 
lesion.  More than a 30% and 0.8-unit increase is SUL peak or new lesions is classified as 
progressive disease.
11.3.2 RECIST Criteria for Tumor Response
Response criteria will be asse ssed using RECIST (version 1.1).[ 55]
Evaluation of target lesions:
Complete Response (CR): Disappearance of all target lesions
Partial Response (PR): At least a 30% decrease in the sum of the  longest 
diameter (LD) of target lesions , taking as reference the baseli ne sum LD
Progressive Disease (PD): At least a 20% increase in the sum of the LD of target 
lesions, taking as reference the smallest sum LD recorded since  the treatment started or 
the appearance of one  or more new lesions
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest su m LD since the treatment 
started
Evaluation of best overall response:
The best overall response is the best response achieved prior t o surgical resection of the 
target lesion.
Target Lesions New Lesions Overall Response
CR No CR
PR No PR
SD No SD
PD Yes or No PD
Any Yes PD
7487
Version 8.0 02Mar2016 Page 52 of 71Note:
In some circumstances, it may be difficult to distinguish resid ual disease from normal 
tissue.  When the evaluation of c omplete response depends upon this determination, 
this will be determined at the time of surgical resection.
11.3.3 Pathologic Response at Surgery
All specimens of primary  tumor will be examin ed for pathologic response at the time of 
surgery.  The study pathologist will estimate the amount of via ble tumor, and report the 
percentage of necrosis.  For purpos e of analysis, tumors will b e classified as either 
t95% necrosis or <95% necrosis.
11.3.4 Duration of Response/Stable Disease
The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or 
progressive disease is objectivel y documented (taking as refere nce for progressive 
disease the smallest measurements  recorded since the treatment started).
The duration of overall CR is measured from the time measuremen t criteria are first 
met for CR until the first date t hat recurrent disease is objec tively documented.
Stable disease is measured from the start of the treatment unti l the criteria for 
progression are met, taking as reference the smallest measureme nts recorded since the 
treatment started. 
11.3.5 Definition of Disease Progression
Disease progression will be defined as:
xRadiologic progression of disease by FDG PET PERCIST 1.0 criter ia
xRadiologic progression of disease by RECIST (version 1.1) criteri a.
11.3.6 Time-to-Event Measures
Time to Local Recurrence- Defined as the duration of time from s urgical resection of 
the primary tumor until local rec urrence (amputated patients excluded).
Local Disease-Free Survival- Defined as the duration of time fro m surgical resection of 
the primary tumor until local rec urrence or death, whichever occurs first.
Distant Disease-Free Survival - Defined as the duration of time f rom randomization
until development of distant metastatic disease or death, which ever occurs first.  
Subjects with stage IV disease will be censored from this analy sis.
Disease-Free Survival - Defined as the duration of time from surg ical resection to local 
recurrence, distant metastatic disease, or death, whichever occ urs first.  Subjects with 
stage IV disease will be censored from this analysis.
7487
Version 8.0 02Mar2016 Page 53 of 71Progression-Free Survival - Defined as the duration of time from randomization to 
progressive disease (per RECIST), local recurrence, distant met astatic disease 
(exclusive of stage IV subject s), or death, whichever occurs first.
Overall Survival - Defined as the interval of time from randomiza tion until death from 
any cause.
11.4 Determining Response to Pazop anib for Continuing on Mainten ance
Subjects who have a partial re sponse by either RECIST 1.1 crite ria on CT or MRI, 
and/or PERCIST 1.0 criteria by FDG PET after the 14 day Run-in period on pazopanib 
will have the option to remain on pazopanib for one year of the rapy following surgery 
and adjuvant chemoth erapy/radiation.
12.0 DATA MANAGEMENT/CONFIDENTIALITY
The Investigator will ensure that data collected conform to all  established guidelines.  Each subject is 
assigned a unique patient numbe r to assure subject confidential ity.  Subjects will not be referred to by 
this number, by name, or by any other individual identifier in any publication or external presentation.
The licensed medical records department, affiliated with the in stitution where the subject receives 
medical care, maintains all or iginal inpatient and outpatient c hart documents.  
Subject research files including  paper and electronic case repor t forms, diagnostic pathology reports, and 
lab tests will be stored in a secure location that protects conf idential information.
13.0 CORRELATIVE STUDIESPlasma will be collected for measurement of VEGF and soluble VEGFR2 (sVEGFR2) at baseline, after 
the 14 day Run-in period of paz opanib, after completion of neoa djuvant chemotherapy and every 3 
months thereafter until comple tion of pazopanib maintenance the rapy, when indicated.  
Quantitative enzyme-linked immunosor bent assays (ELISA) for VEG F and sVEGFR2 will be
performed on plasma and tumor extracts.
MicroRNAs have been shown to be pr omising blood and tissue-base d markers for cancer detection.[56]
An extension of this is that suc h markers may also be excellent  candidates for measuring response to 
therapy.  There are currently  no validated biomarkers to predict response to antiangiogenic therapy.
Consequently, the ability to test candidate microRNA biomarkers before, during and after neoadjuavnt 
systemic therapy offers an ideal setting to assess potential bi omarkers. Blood samples  will be collected 
for micro RNA at baseline, a fter the 14 day Run-in period of pazopanib, following neoadjuvant 
chemotherapy and every 3 months  thereafter until completion of pazopanib maintenance therapy, when 
indicated.Samples to be teste d will be an additional  3 tablespoons of whole  blood (23cc) at each time of clinical 
lab draw, collected as 10cc int o EDTA tubes (plasma), 10cc into  serum separator tubes, and 3cc into 
Tempus tubes (containing an RNA stabilizer).
7487
Version 8.0 02Mar2016 Page 54 of 71There may also be evaluation of other potential predictive and prognostic markers using analysis of 
protein, DNA and RNA from s urgical tumor tissue.
14.0 STATISTICAL CONSIDERATIONS
14.1 Analysis plan
The primary objective is to compare  FDG SUV (SUV lean, SUL) meas ures for patients receiving 
pazopanib and placebo.  Th e primary endpoint is the percent cha nge in SUV between baseline 
and the end of the 14-day Run- in period of pazopanib or placebo .  The comparison will likely be 
conducted using a two-sided Wilc oxon rank sum test, often used a s a nonparametric alternative 
to the two-sample t-test for st udies with a small sample size.  Additional endpoints will include 
SUV percentage change between b aseline and the end of preoperat ive therapy, absolute post-
treatment SUV (at 14 days and fo llowing preoperative chemothera py), and absolute difference in 
SUV.  
The analysis sample for the pr imary pharmacodynamic analysis is  expected to e xclude patients 
who have incomplete data due to missed PET scans or due to stud y withdrawal for toxicity.   
However, reasons for missing  data will be exa mined, and multiple imputation will be considered 
if patients with incomplete data would be c onsidered as part of  the target population for future 
development of pazopanib in sarco ma.  However, insofar as sarcoma is heterogeneous, the 
sample size is sma ll, and covariates are  limited ‚Äì multiple impu tation may not be applicable.
These pharmacodynamic response m easures will be compared to tum or response by RECIST 
criteria, using graphical displ ays.  Continuous measures of pha rmacodynamic response 
(percentage change in SUL; response assessed using MRI) will also be compared to the trough 
plasma pazopanib, using graphical displays and correlation coef ficients to investigate dose-
response relationships relate d to patients‚Äô differing metabolis m of pazopanib.
Descriptive displays of preliminar y clinical endpoints (patholo gic response, progression-free 
survival, overall survival) will compare response for the pazop anib and placebo groups, and will 
investigate the relationship betw een early pharmacodynamic resp onse (by PET) and clinical 
endpoints.  Response of high-ris k soft tissue sarcoma to neoadj uvant chemoradiation therapy was 
estimated as 52% (38% no residua l tumor, 14% >=95 pathologic ne crosis) in a series of 496 
patients.[9] A smaller seri es found only 13/46 (28%) with <10% viable tumor in surgical 
specimens following a variety of neoadjuvant regimens.[51] To direct planning of future studies,we will measure the rate of comp lete pathological response defi ned as greater than 95% necrosis 
in the surgical excision spec imen. A 90% Wilson ( score) binomial  confidence interval will be 
computed for the rate of com plete pathological response.
There are no stopping rules planne d for toxicity, but safety wi ll be monitored continuously. All 
subjects who are registered and receive at least one dose of st udy drug will be included in the 
safety analysis.
7487
Version 8.0 02Mar2016 Page 55 of 71All reported adverse e vents will be coded usin g the Cancer Ther apy Evaluation Program (CTEP) 
Common Toxicity Criteria version 4.0.  The number and percent of  subjects reporting adverse 
events (all, severe or worse, serious and related) will be quan tified.  Listings w ill be provided for 
all on-study deaths and adverse ev ents that lead to withdrawal from study.  Narratives of all 
serious adverse events and d eaths on-study will be provided.  
Correlative study assays will be a nalyzed using descriptive sta tistics, generally comparing 
pazopanib and placebo groups. Corre lation will also be evaluate d between pazopanib trough 
concentrations and drug exposure  over the dosing interval (area -under-the-concentration-curve, 
AUC) in subjects consenting to the  full intensive pharmacokinet ic visits.
14.2 Sample size justification
If the standard deviation for pe rcent change in is 20% and the average change is 0% for placebo 
and a 30% decrease for pazopanib, t here will be approximately 90%  power to detect a difference 
between the placebo and pazopani b group in average percent chan ge for n=21 and a 2:1 
randomization.
14.3 Protocol Enrollment a nd Special Considerations
The ethnic and gender distributi on chart below reflects estimat es of race and gender of the 
population to be included in this study. 
TARGETED / PLANNED ENROLLMENT:  Number of Subjects
Ethnic CategorySex / Gender
Females Males Total
Hispanic or Latino 0 0 0
Not Hispanic or Latino 10 11 21
Ethnic Category Total of All Subjects* 10 11 21
a) Racial Categories
American Indian / Alaska Native 0 0 0
Asian 0 0 0
Native Hawaiian or Other Pacific Islander 0 0 0
Black or African American 0 0 0
White 10 11 21
Racial Categories:  Total of All Subjects* 10 11 21
15.0 RECORDS
15.1 Source Documents
Source documents provide evidence for the existence of the patient and substantiate the integrity 
of the data collecte d.  Source documents are filed at the inves tigator‚Äôs site.  The collaborating site 
7487
Version 8.0 02Mar2016 Page 56 of 71will send signed consents and eligibility forms to the coordina ting center with source documents 
demonstrating subject eligibility within 10 business days of en rollment.
Data entered in the CRF transcribed from source documents must b e consistent with the source 
documents or the discrepancies must be explained.  The investig ator may need to request 
previous medical records or trans fer records.  Cur rent medical records must be available.
All data entered in t o the CRF must be derived from source docu ments.  CRF data will be 
submitted to the coordinating center by entry into REDCapTM.  Data entered into the CRF will be 
reviewed for accuracy against  source documentation per section 9.0.  
15.2 Access
The investigator and/or institu tion will permit study-related m onitoring, audits, EC review and 
regulatory inspection, providing  direct access to all related s ource data and documents.  The 
study is monitored per secti on 9.0, which details t he full scope and extent of monitoring and 
provides for immediate action in t he event of the discovery of major violations.  CRFs and all 
source documents, including prog ress notes and copies of labora tory and medical test results 
must be available at all times fo r review by the clinical study  monitor, auditor and inspection by 
health authorities.  The Clinical R esearch Associate (CRA) or auditor my review all CRFs and 
written informed consen ts.  The accuracy of  the data will be verified per section 9.0.
16.0 TERMINATION OF STUDY
The PI/IND sponsor may terminate the study at any time.  The IR B and FDA also have the 
authority to terminate the study should it be deemed necessary.
REFERENCES
[1] Delaney TF, Yang JC, Glatstein E. Adjuvant therapy for adult  patients with soft tissue sarcomas. 
Oncology 1991;5:105-18.
[2] Weitz J, Antonescu CR, Brennan MF: Localized extremity soft tissue sarcoma; improved 
knowledge with unchang ed survival over time. J Clin Oncol 2003;21:2719-25.
[3] Adjuvant chemotherapy for loca lized resectable soft-tissue s arcoma of adults: meta-analysis of 
individual data. Sarco ma Meta-analysis Collaboration. Lancet 19 97;350:1647-1654.
[4] Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemo therapy for adult soft tissue 
sarcomas of the extremities and girdles: results of the Italian  randomized coopera tive trial. J Clin 
Oncol 2001;19:1238-1247.
[5] Frustaci S, De Paoli A, Bido li E, et al. Ifosfamide in the a djuvant therapy of soft tissue sarcomas. 
Oncology 2003;65 (Suppl 2):80-84.
[6] Pervaiz N, Colterjohn N, Farrokh yar F et al. A systematic meta-analysis of randomized 
controlled trials of adjuvant chemotherapy for localized resect able soft-tissue sarcoma. Cancer 
2008;113:573-81.
[7] Gortzak E, Azzarelli A, Buesa  J et al. A randomized phase II  study on neoadjuvant 
chemotherapy for ‚Äòhigh risk‚Äô adu lt soft-tissue sarcoma. Eur J C ancer 2001;37:1096-1103.
[8] Grobmeyer SR, Maki RG, Demetri  GD et al. Neo-adjuvant chemot herapy for primary high-grade 
extremity soft tissue sarcoma.  Ann Oncol 2004;15:1667-72.
7487
Version 8.0 02Mar2016 Page 57 of 71[9] Eiber FC, Rosen G, Eckardt J , et al et al. Treatment-induced  pathologic necrosis : a predictor of 
local recurrence and survival i n patients receiving neoadjuvant therapy for high-grade extremity 
soft tissue sarcomas. J Clin Oncol 2001;19:3203-09.
[10] Folkman J. Tumor angiogenesi s: therapeutic implications. N Engl J Med 1971;285:1182-6.
[11] Grimbone MA, Leapman S, Cotran RS, et al. Tumor dormancy in vivo by prevention of 
neovascularizati on. J Exp Med 1972;136:261-76.
[12] Liotta L, Kleinman J, Saldel G. Quantitative relationships of intravascular t umor cells, tumor 
vessels, and pulmonary metastases following tumor implantation.  Cancer Res 1974;34:997-1004.
[13] Folkman J. What is the evidence that tumors are angiogenesi s dependent? J Natl Cancer Inst 
1990; 82:4-6.
[14] Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and 
leucovorin for metastatic color ectal cancer. N Engl J Med 2004;  350:2335-42.
[15] Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-
small-cell lung cancer. N Engl J Med 2006;355:2542-50 .
[16] Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanc ed clear-cell renal-cell carcinoma. N 
Engl J Med 2007;356:125-34.
[17] Llovet J, Ricci S, Mazzagerr o V, et al. Sorafenib improves survival in advanced Hepatocellular 
Carcinoma (HCC): Resu lts of a Phase III randomized placebo-cont rolled trial (SHARP trial). 
Proc Am Soc Clin Oncol 2007;25:18S.
[18] Motzer RJ, Hutson TE, Tomcz ak P, et al. Sunitinib versus in terferon alfa in met astatic renal-cell 
carcinoma. N Engl J Med 2007;356:115-24.
[19] Hayes AJ, Mostyn-Jones A, Koban MU, et al. Serum vascular endothelial growth factor as a 
tumour marker in soft tissue sarcoma. Br J Surg 2004;91:242-7.
[20] Potti A, Ganti AK, Tendulkar K, et al. Determination of vascular endothelial growth factor 
(VEGF) overexpression in soft tissue sarcomas and the role of o verexpression in 
leiomyosarcoma. J Cancer  Res Clin Oncol 2004;130:52-6.
[21] Yudoh K, Kanamori M, Ohmori K, et al. Concentration of vasc ular endothelial growth factor in 
the tumour tissue as a prognostic factor of soft tissue sarcoma s. Br J Cancer 2001;84:1610-5.
[22] Graeven U, Andre N, Achilles E, et al. Serum levels of vasc ular endothelial growth factor and 
basic fibroblast growth factor i n patients with soft-tissue sar coma. J Cancer Res Clin Oncol 
1999;125:577-81.
[23]. Yoon SS, Segal NH, Olshen AB, et al. Circulating angiogeni c factor levels correlate with extent 
of disease and risk of recurrenc e in patients with soft tissue sarcoma. Ann Oncol 2004;15:1261-
6.
[24]. Yoon SS, Segal NH, Park PJ, e t al. Angiogenic profile of so ft tissue sarcomas based on analysis 
of circulating factors and micro array gene expression. J Surg R es 2006;135:282-90.
[25] Wang J, Coltrera MD, Gown A M. Cell proliferation in human soft tissue tumors correlates with 
platelet-derived gro wth factor-B chain expression: An immunohis tochemical and in situ 
hybridization assay. Cancer Res 1994;54:560‚Äî564.
[26] George S, Merriam P, Maki RG , et al. Multicenter phase I tr ial of sunitinib in the treatment of 
nongastrointestinal stromal tum or sarcomas. J Clin Oncol 2009;27:3154-60.
[27] Maki RG, D‚ÄôAdamo D R, Keohan ML, et al. Phase II study of so rafenib in patients with 
metastatic or rec urr
ent sarcomas. J Clin Oncol 2009;27:3133-40.
7487
Version 8.0 02Mar2016 Page 58 of 71[28] Harris PA. Discovery of  5-[[4-[(2,3-dimethyl-2 H-indazol-6-yl)methylaminol]-2-
pyrimidinyl]amino]-2-methylbenzenesulfonamide (pazopanib), a no vel and potent vascular 
endothelial growth factor recepto r inhibitor. J Med Chem 2008;5 1:4632-40.
[29] Kumar R. Pharmacokinetic-pha rmacodynamic correlation from mouse to human with pazopanib, 
a multi-kinase angiogenesis inhi bitor with potent antitumor and antiangiogenic activity. Mol 
Cancer Ther 2007;6:2012-21.
[30] Bukowski RM, Yasothan U, K irkpatrick P. Pazopanib. Nature R eviews 2010;9:17-18.
[31] Sternberg CN, Davis ID, Mar diak J et al. Pazopanib in local ly advanced or metastatic renal cell 
carcinoma: results of a randomize d phase III trial. J Clin Onco l 2010;28:1061-68.
[32] Sleijfer S, Ray-Coquard I, P apai Z, et al. Pazopanib, a mul tikinase angiogenesis inhibitor, in 
patients with relapsed or refract ory advanced soft tissue sarco ma: a phase II study from the 
European Organisation for Research and Treatment of Cancer-Soft Tissue Bone Sarcoma Group 
(EORTC study 62043).  J Clin Oncol 2009;27:3126-32.
[33] Zhang L, Hannay JA, Liu J, et al. Vascular endothelial grow th factor overexpression by soft 
tissue sarcoma cells: implications  for tumor growth, metastasis, and chemoresistance. Cancer 
Res 2006;66:8770-8.
[34] GW786034 Investigator‚Äôs Brochure, Version 14 (January 2016). Novartis, East Hanover, NJ.
[35] Cheung, M., A. Boloor, and K.W . Hinkle.  Discovery of indaz olylpyrimidines as potent 
inhibitors of VEGFR2 tyrosine ki nase. Proc AACR- NCI-EORTC Intl Conf Mol Targets Cancer 
Therapy 2003; Abstr. C42
[36] Kumar, R., L.E. Harrington, T.M. Hopper ,et al. Correlation of anti- tumor and anti-angiogenic 
activity of VEGFR inhibitors with inhibition of VEGFR2 phosphor ylation in mice.  J Clin Oncol 
2005; 23 (suppl):A9537.
[37] Sternberg CN, Davis ID, Mar diak J, et al. Pazopanib in loca lly advanced or metastatic renal cell 
carcinoma: results of a randomized phase III trial. J Clin Oncol  2010. In press.
[38] Altorki N, Guarino M, Lee P , et al. Preoperative treatment with pazopanib (GW786034)
a multikinase angiogenesis inhibitor in early stage non-small c ell lung cancer (NSCLC): a
proof-of-concept phase II stud y.  J Clin Oncol 2008; 26 (suppl): A7557.
[39] Taylor, S.K., S. Chia, S. Dent ,et al. A phase II study of Paz opanib (GW786034) in subjects wit h 
recurrent or metastatic invasive  breast carcinoma: Results afte r completion of stage I: A trial of
the Princess Margaret Hospital Phase II Consortium. J Clin Onco l. 2009; 27 (suppl):A1133.
[40] Slamon D, Gomez HL, Amit O, e t al. Pazopanib + Lapatinib is  more active than Laptinib alone: 
Updated results from a randomize d study in subjects with first- line ErbB2-positive advanced or 
metastatic breast cancer [E SMO abstract 139P].  Ann Oncol .2008; 19 (supp 8):viii 64-65.
[41] Monk, B., L. Mas, J.J. Zarba , et al. A randomized phase II study: Pazopanib (P) versus lapatinib 
(L) versus combination of pazopani b/lapatinib (L+P) in advanced and recurrent cervical cancer 
(CC).  J Clin Oncol .2009; 27 (suppl):A5520.
[42] B
ible, K.C., R.C. Smallridge, W .J. Maples, et al. Phase II trial of pazopanib in progressive, 
metastatic, iodine-insensitive differentiated thyroid cancers. J  Clin Oncol. 2009; 27 
(suppl):A3521.
[43] Hurwitz, H.I., A. Dowlati, S. Saini ,et al. Phase I trial of pa zopanib in subjects with 
advanced cancer. Clin Cancer Res. 2009; 15:4220-4227.
[44] DePrimo, S.E., C.L. Bello, J. S meraglia, et al. Circulating  biomarkers of pharmacodynamic 
activity of sunitinib in subjects with metastatic renal cell ca rcinoma: modulation of VEGF and 
VEGF-related proteins. J Trans Med. 2007; 5:32-43.
[45] Therasse P, Arbuck SG, Eise nhauer EA. New guidelines to eva luate the response 
to treatment in solid tumors. E uropean Organization for Researc h and Treatment
7487
Version 8.0 02Mar2016 Page 59 of 71of Cancer, National Cancer Institute of the United States, Nati onal Cancer Institute of Canada. J
Natl Cancer Inst 2000;92:205-216.
[46] Panicek DM, Casper ES, Brenn an MF. Hemorrhage simulating tu mor growth in malignant 
fibrous histiocytoma at MR imaging. Radiology 1991;181:398-400.
[47] Pisters PWT, Patel SR, Varma DGK, et al. Preoperative chemotherapy for stage IIIB extremity 
soft tissue sarcoma: long term results from a single institution . J Clin Oncol 1997;15:3481-87.
[48] Meric F, Hess KR, Varma DGK , et al. Radiographic response to neoadjuvant chemotherapy is a 
predictor of local control and s urvival in soft tissue sarcomas . Cancer 2002;95:1120-1126.
[49] Delaney TF, Spiro IJ, Suit HD, et al. Neoadjuvant chemother apy and radiotherapy for large 
extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 2003;56:1117-27.
[50] Eary JF, O‚ÄôSullivan F, Pow itan Y. Sarcoma tumor FDG uptake measured by PET and patient 
outcome: a retrospective analys is. Eur J Nucl Med Mol Imaging 2002;29;1149-54.
[51] Schuetze SM, Rubin BP, V ernon C. Use of positron emission tomography in loc alized extremity 
soft tissue sarcoma treated wit h neoadjuvant chemotherapy. Canc er 2005;103:339-348.
[52] Eary JF, Mankoff DA. Tumor metabolic rates in sarcoma using  FDG PET. J Nucl Med 
1998;39:25-54.
[53] Shankar LK, Hoffman JM, Bacharach S, et al. Consensus recom mendations for  the use of 18F-
FDG PET as an indicator of therape utic response in patients in National Cancer Institute Trials. J 
Nucl Med 2006;47:1059-1066.
[54] Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST : Evolving considerations for 
PET response criteria in soli d tumors. J Nuc Med 2009;50:122S-1 50S.
[55] Eisenhauer EA, Therasse P, B ogaerts J, et al. New response evaluation criteria in solid tumours: 
revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
[56] Mitchell PS, Parkin RK, Kroh E M, et al. Circulating microRN As as stable blood-based markers 
for cancer detection. Proc Na tl Acad Sci USA 2008;105(30):10513 -8.
[57]     van der Graaf WT, Blay JY , Chawla SP et al. Pazopanib for metastatic  soft-tissue sarcoma  
(PALETTE): a randomized, double-blind, placebo controlled phase  3 trial. Lancet
2012;379:1879-86.
7487
Version 8.0 02Mar2016 Page 60 of 71APPENDIX A: Study Activities and Treatment Calendar
 Screening End of Week 
Two Prior to Day 1 
of each cycle After 2 cycles of preop 
chemo At time of 
surgery Post-treatment 
follow-up every 4 
weeks if 
receiving pazopanib, 
else  every 
3 months 
Informed Consent X      
History/Progress Notes X X X   X 
Physical Exam X X X   X 
Vitals signs X X X   X 
Performance Status X X X   X 
Treatment Toxicity   X X   X 
Pathology Review X    X  
CBC, chemistries, 
Ca++, phos, Mg+ , 
hepatic panel X X X   X 
UA X  X   X 
Pregnancy test X      
INR X      
ECG X X    X  
(every 3 
months) 
ECHO X      
Tissue/blood for 
correlative 
studies X X  X X X   
(every 3 months) 
FDG-PET X X  X   
MRI X X  X   
Plasma pazopanib trough level  X (2 visits)    X  
(every 3 months) 
Full plasma pazopanib PK 
(optional)      X (once 
during Weeks 2-4) 
CT-chest X     X  
(every 3 
months) 
7487
Version 8.0 02Mar2016 Page 61 of 71APPENDIX B
Performance Status Criteria
ECOG Performance Status Scale Karnofsky Performance Scale
Grade Descriptions Percent Description
0Normal activity.  Fully active, able to 
carry on all pre-disease performance 
without restriction.100Normal, no complaints, no evidence of disease.
90Able to carry on normal activity; minor signs or symptoms of disease.
1Symptoms, but ambulatory.  Restricted in 
physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g. , light 
housework, office work).80Normal activity with effort; some signs or symptoms of disease.
70Cares for self, unable to carry on normal activity or to do active work.
2In bed <50% of the time.  Ambulatory and capable of all self-care, but unable to 
carry out any work activities.  Up and 
about more than 50% of waking hours.60Requires occasional assistance, but is able 
to care for most of his/her needs.
50Requires considerable assistance and frequent medical care.
3In bed >50% of the time.  Capable of only 
limited self-care, confined to bed or chair more than 50% of waking hours.40Disabled, requires special care and assistance.
30Severely disabled, hospitalization indicated.  Death not imminent.
4100% bedridden.  Completely disabled.  Cannot carry on any self-care.  Totally 
confined to bed or chair.20Very sick, hospitalization indicated. Death not imminent.
10Moribund, fatal processes progressing rapidly.
5 Dead. 0 Dead.
7487
Version 8.0 02Mar2016 Page 62 of 71APPENDIX C
Additional Eligibility Criteria for Women
Criteria for women of non-childbe aring potential (physiological ly incapable of becoming 
pregnant):
x A hysterectomy or 
x A bilateral oophorectomy (ovariectomy) or a bilateral tubal lig ation or 
x Is post-menopausal - Subjects not using hormone replacement ther apy (HRT) must have experienced total cessation of 
PHQVHVIRU¬ï\HDUDQGEHJUHDWHUWKDQ\HDUVLQDJH25LQ TXHVWLRQDEOHFDVHVKDYHDIROOLFOHVWLPXODWLQJKRUPRQH
(FSH) value >40 mIU/mL and an estradiol value <40 pg/mL (<140 pm ol/L) or
Subjects using HRT must have experienced total cessation of men ses for ¬ï1 year and be greater 
than 45 years of age OR have had do cumented evidence of menopau se based on FSH and estradiol 
concentrations prio r to initiation of HRT
Criteria for women of c hildbearing potential, including any female who h as had a negative serum 
pregnancy test within 2 weeks prio r to the first d ose of study treatment , preferably as close to the 
first dose as possible, and agr ees to use adequate contraceptio n.  Acceptable methods of contraception 
are: 
Complete abstinence from sexual intercourse for 14 days before exposure to investigational product, 
through the dosing period, and for  at least 21 days after the l ast dose of investigational product 
x Oral contraceptive, either com bined or progestogen alone 
x Injectable progestogen 
x Implants of levonorgestrel 
x Estrogenic vaginal ring 
x Percutaneous contra ceptive patches 
x Intrauterine device (IUD) or intrauterine system (IUS) with a d ocumented failure rate of less than 
1% per year
x Male partner sterilization (vasectomy with documentation of azo ospermia) prior to the female 
subject's entry into the study, and this male is the sole partner for that subje ct 
x Double barrier method:  condom and an occlusive cap (diaphragm or cervical/vault caps) with a 
vaginal spermicidal agent (foam/gel/film/cream/suppository)
7487
Version 8.0 02Mar2016 Page 63 of 71APPENDIX D
Drugs Known to be Metabolized  by Selected CYP 450 Isoenzymes
CYP2C8/9
SUBSTRATES INHIBITORS INDUCERS
Generic Name Trade Name Generic Name Trade Name Generic Name Trade N ame
Antibiotics: e.g.
Rifampin
SulfadiazineRifadin
--Antifungals: e.g.
FluconazoleKetoconazole
Miconazole
TioconazoleDiflucanNizoral
Lotramin 
MonistatSedatives: e.g.
Phenobarbiatl
PrimidoneLuminalMysoline
Misc. CV agents: e.g.
Amiodarone
CarvedilolCordarone
CoregAntimalarials: e.g.
PyrimethamineQuinine    DaraprimLegatrinAnticonvulsants: e.g.
Carbamazapine
Phenobarbital
PhenytoinTegretolLuminal
Dilantin
Anti-asthmatics: e.g.
Montelukast
ZafirlukastSingulair
AccolateAnti-hyperlipidemics: e.g.
     Fluvastatin
GemfibrozilLescolLopidAntibiotics: e.g.
RifapentineRifampinPriftinRifadin
Antidepressants: e.g.
Fluoxetine
SertralineProzacZoloftAntibiotics: e.g.
IsoniazidSulfadiazine
Sulfamethoxazole
TrimethoprimINH, Nydrazid
--
Bactrim, Septra
Primsol
Anticonvulsants: e.g.
Fosphenytoin
PhenytoinCerebyxDilantinAnalgesics: e.g.
FlurbiprofenIbuprofenIndomethacin
Mefenamic acidAnsaidAdvil, MotrinIndocin
Ponstel
Anesthetics: e.g.
Ketamine
PropofolKetalar
DiprivanAnti-ulceratives: e.g.
Omeprazole
PantoprazolePrilosecPantoloc
Anti-diabetics: e.g.
     Glimepiride     RosiglitazoneAmarylAvandiaAntihypertensives: e.g.
IrbesartanLosartan
NicardipineAvaproCozaar
Cardene
Antihypertensives: e.g.
Losartan
BosentanCozaar
Tracleer
Paclitaxel Taxol Anti-diabetics: e.g.
Pioglitazone
RosiglitazoneActosAvandia
Alosetron Lotronex Amiodarone Cordarone
Torsemide Demadex Delavirdine Rescriptor
Piroxicam Feldene
Warfarin Coumadin
Zafirlukast Accolate
When drugs classified as ‚Äòsubstrates‚Äô are co-administered with (Study Agent) , there is the potential for higher concentrations of the ‚Äòsubs trate‚Äô. When  (Study 
Agent) is co-administered with compounds classified as ‚Äòinhibitors‚Äô, i ncreased plasma concentrations of  (Study Agent) is the potential outcome. The 
coadministration of ‚Äòinducers‚Äô would potentially lower plasma   (Study Agent) concentrations.
7487
Version 8.0 02Mar2016 Page 64 of 71Comprehensive list of drugs that may have potential interaction s
CYP2C8/9
SUBSTRATES
Alosetron
Amiodarone
Bosentan
CarvedilolFluoxetine
Fosphenytoin
GlimepirideGlipizide
KetamineLosartan
Mephenytoin
Mestranol
MontelukastNateglinide
Paclitaxel
PhenytoinPioglitazone
PropofolRifampin
Rosiglitazone
Selegiline
SertralineSulfadiazine
Sulfamethoxazole
SulfinpyrazoneSulfisoxazole
TamoxifenTolbutamide
Torsemide
Trimethoprim
VoriconazoleWarfarin
Zafirlukast
Zopiclone
INHIBITORS
Amiodarone
Amitryptiline
AmlodipineAnastrozole
Aprepitant
AtazanavirAzelastine
Bortezomib
CandesartanChloramphenicol
Cholecalciferol (Vitamin D
3)
Cimetidine
Clopidogrel
Clotrimazole
ClozapineCyclosporine
Delavirdine
DexmedetomidineDiclofenac
Diltiazem
Dimethyl sulfoxideDisulfiram
Drospirenone
EfavirenzEntacapone
Eprosartan
EtoposideFelodipine
Fluconazole
FluoxetineFluphenazine
Flurbiprofen
FluvastatinFluvoxamine
Gemfibrozil
IbuprofenImatinib
Indinavir
IndomethacinIrbesartan
Isoniazid
KetoconazoleKetoprofen
Lansoprazole
LeflunomideLosartan
Lovastatin
Mefenamic acidMeloxicam
Methimazole
MethoxsalenMetronidazole
Miconazole
MidazolamModafinil
Montelukast
NateglinideNelfinavir
Nicardipine
NifedipineOlanzapine
Omeprazole
OndansetronOrphenadrine
Pantoprazole
ParoxetinePentamidine
Pioglitizone
PiroxicamPravastatin
Progesterone
PropafenonePropofol
Propoxyphene
PyrimethamineQuinidine
Quinine
RitonavirRosiglitazone
Saquinavir
SelegilineSertraline
Sildenafil
SimvastatinSulconazole
Sulfadiazine
SulfamethoxazoleSulfinpyrazone
Sulfisoxazole
TamoxifenTeniposide
Thioridazine
TiclopidineTioconazole
Tolbutamide
TolcaponeTranylcypromine
Tretinoin
TriazolamTrimethoprim
Valdecoxib
Valproic acidValsartan
Verapamil
VoriconazoleWarfarin
Zafirlukast
INDUCERS
Carbamazepine
FosphenytoinPhenobarbitalPhenytoinPrimidoneRifampinRifapentineSecobarbital
(Adapted from Cytochrome P-450 Enzymes and Drug metabolism.  In : Lacy CF, Armstrong LL, Goldman MP, Lance LL eds. Drug Informat ion Handbook 
12THed. Hudson, OH; LexiComp Inc. 2004: 1619-1631.)
7487
Version 8.0 02Mar2016 Page 65 of 71Selected Potential Cytochrome P450 (CYP) Drug Interactions
CYP3A4
SUBSTRATES INHIBITORS INDUCERS
Generic Name Trade Name Generic Name Trade Name Generic Name Trade N ame
Anti-neoplastics: e.g.
Docetaxel
Gefitinib
IrinotecanTaxotereIressa
CamptosarAnti-arrhythmics: e.g.
Amiodarone
Diltiazem
QuinidineCordarone, PaceroneCardizem, Dilacor XR
CardioquinAminoglutethimide Cytadren
Anti-virals: e.g.
Amprenivir
RifampinAgenerase
RifadinAnti-virals: e.g.
AmprenavirIndinavir
Nelfinavir
RitonavirAgenerase
Crixivan
Viracept
NorvirAntibiotics: e.g.
Rifabutin
RifampinRifadinMycobutin
Anxiolytics: e.g.
Diazepam
SertralineValiumZoloftCimetadine Tagamet Anticonvulsants: e.g.
Carbamazapine
PhenytoinPentobarbital
PhenobarbitalTegretolDilantinNembutal
Luminal
Cyclosporine Sandimmune Cyclosporine Sandimmune Hypericum perforatum (2) St. John‚Äôs Wort
Anti-infectives: e.g.
Erythromycin
TetracyclineErythrocin
SumycinAntibiotics: e.g.
CiprofloxacinClarithromycin
Doxycycline
Enoxacin
Isoniazid
TelithromycinCipro, CiloxanBiaxinAdoxa, Periostat
Penetrex
Nydrazid, INH
Ketek
Steroids: e.g.
Estrogens, conjugated
Estradiol
ProgesteronePremarinClimaraCrinoneImatinib Gleevec
Haloperidol Haldol Haloperidol Haldol
Cardiovascular agents: e.g.
Digitoxin
QuinidineCrystodiginCardioquinDiclofenac Cataflam, Voltaren
Anti-hypertensives: e.g.
Nicardipine
VerapamilCardeneCalan, ChronoveraVasodilators: e.g.
Nicardipine
VerapamilCardeneCalan, Chronovera
Anesthetics: e.g.
Ketamine
LidocaineXylocaineDiprivanAnesthetics: e.g.
Lidocaine
PropofolXylocaineDiprivan
Nefazodone Serzone Anti-depressants: e.g.
Nefazodone
SertralineSerzoneZoloft
Cocaine Anti-fungals: e.g.
Itraconazole
Ketoconazole
MiconazoleSporanoxNizoral
Lotrimin, Monistat
Ketoconazole Nizoral Caffeine
Sildenafil Viagra Grapefruit juice (1)
Albuterol Ventolin
Carbamazapine Tegretol
Lovastatin Mevacor
When drugs classified as ‚Äòsubstrates‚Äô are co-administered with (Study Agent) , there is the potential for higher concentrations of the ‚Äòsubs trate‚Äô.  When  (Study 
Agent) is co-administered with compounds classified as ‚Äòinhibitors‚Äô, i ncreased plasma concentrations of  (Study Agent) is the potential outcome.  The 
coadministration of ‚Äòinducers‚Äô would potentially lower plasma   (Study Agent) concentrations.
7487
Version 8.0 02Mar2016 Page 66 of 71Comprehensive List of Drugs That May Have Potential Interaction s
CYP3A4
SUBSTRATES
Albuterol
Alfentanil
Alprazolam
AmlodipineAmprenavir
Aprepitant
AripiprazoleAtazanavir
Atorvastatin
BenzphetamineBisoprolol
Bortezomib
BosentanBromazepam
Bromocriptine
BuprenorphineBuspirone
Busulfan
Carbamazapine
Cerivastatin
ChlordiazepoxideChloroquine
Chlorpheniramine
CisaprideCitalopram
Clarithromycin
ClobazamClonazepam
Clorazepate
CocaineColchicine
Cyclophosphamide
CyclosporineDantrolene
Dapsone
DelavirdineDiazepam
Digitoxin
DihydroergotamineDiltiazem
DisopyramideDocetaxel
Doxepin
Doxorubicin
Doxycycline
Efavirenz
Eletriptan
EnalaprilEplerenone
Ergoloid mesylates
ErgonovineErgotamine
Erythromycin
EscitalopramEsomeprazol
Estradiol
Estrogens, conj., syntheticEstrogens, conj., equine
Estrogens, conj., esterified
Estrone
Estropipate
Ethinyl estradiolEthosuximide
Etoposide
FelbamateFelodipine
Fentanyl
FlurazepamFlutamide
Fosamprenavir
FulvestrantGefitinib
Halofantrine
HaloperidolIfosfamide
Imatinib
IndinavirIrinotecan
Isosorbide dinitrate
Isosorbide mononitrateIsradipine
Itraconazole
KetamineKetoconazole
Lansoprazole
Letrozole
Levomethadyl acetate
hydrochloride
LevonorgestrelLidocaineLosartan
Lovastatin
Medroxyprogesterone Mefloquine
Mestranol
MethadoneMethylergonovine
Methysergide
MiconazoleMidazolam
Miglustat
Mirtazapine
Modafinil
MontelukastMoricizine
Nateglinide
NefazodoneNelfinavir
Nevirapine
NicardipineNifedipine
Nimodipine
NisoldipineNitrendipine
Norethindrone
NorgestrelOndansetron
Paclitaxel
PergolidePhencyclidine
Pimozide
PioglitazonePrimaquine
ProgesteroneQuetiapine
Quinidine
Rabeprazole
RepaglinideRifabutin
Rifampin
RitonavirSaquinavir
Sertraline
SibutramineSildenafil
Simvastatin
SirolimusSufentanil
Tacrolimus
Tamoxifen
Tams
ulosin
TelithromycinTeniposide
Terbinafine
TetracyclineTheophylline
Tiagabine
TiclopidineTolterodine
Toremifene
TrazodoneTriazolam
Trimethoprim
TrimipramineTroleandomycin
Vardenafil
VenlafaxineVerapamil
Vinblastine
VincristineVinorelbine
Zolpidem
ZonisamideZopiclone
7487
Version 8.0 02Mar2016 Page 67 of 71CYP3A4
INHIBITORS
Acetominophen
Acetazolamide
Amioderone
AmlodipineAmprenavir
Anastrozole
AprepitantAtazanavir
Atorvastatin
AzelastineAzithromycin
Betamethasone
BortezomibBromocriptine
Caffiene
CerivastatinChloramphenicol
Chlorzoxazone
CimetadineCiprofloxacin
Cisapride
ClarithromycinClemastine
Clofazimine
ClotrimazoleClozapine
Cocaine
CyclophosphamideCyclosporine
Danazol
DelavirdineDesipramine
Dexmedetomidine
DiazepamDiclofenac
DihydroergotamineDiltiazem
Disulfiram
Docetaxel
DoxorubicinDoxycycline
Drospirenone
EfavirenzEnoxacin
Entacapone
ErgotamineErythromycin
Ethinyl estradiol
EtoposideFelodipine
Fentanyl
FluconazoleFluoxetine
Fluvastatin
FluvoxamineFosamprenavir
Glyburide
Grapefruit juiceHaloperidol
Hydralazine
IfosfamideImatinib
Indinavir
IrbesartanIsoniazid
Isradapine
ItraconazoleKetoconazole
Lansoprazole
LidocaineLomustine
LosartanLovastatin
Mefloquine
Mestranol
MethadoneMethimazole
Methoxsalen
MethylprednisoloneMetronidazole
Miconazole
MidazolamMifepristone
Mirtazapine
MitoxantroneModafinil
Nefazodone
NelfinavirNevirapine
Nicardipine
NifedipineNisoldipine
Nitrendipine
NizatidineNorfloxacin
Olanzapine
OmeprazoleOrphenadrine
Oxybutynin
ParoxetinePentamidine
Pergolide
PhencyclidinePilocarpine
Pimozide
PravastatinPrednisolone
PrimaquineProgesterone
Propofol
Propoxyphene
QuinidineQuinine
Quinupristin
RabeprazoleRisperidone
Ritonavir
SaquinavirSelegiline
Sertraline
SildenafilSirolimus
Sulconazole
TacrolimusTamoxifen
Telithromycin
TeniposideTestosterone
Tetracycline
TiclopidineTranylcypromine
Trazodone
TroleandomycinValproic acid
Venlafaxine
VerapimilVinblastine
Vincristine
VinorelbineZafirlukast
Ziprasidone
INDUCERS
AminoglutethimideCarbamazapine
FosphenytoinSt. John‚Äôs wortNevirapine
Oxcarbazepine
PentobarbitalPhenobarbitalPhenytoin
Primidone
RifabutinRifampinRifapentine
(Adapted from Cytochrome P-450 Enzymes and Drug metabolism. In:  Lacy CF, Armstrong LL, Goldman MP, Lance LL eds. Drug 
Information Handbook 12THed. Hudson, OH; LexiComp Inc. 2004: 1619-1631.)
(1)  Malhorta et al. (2000). Clin Pharmacol Ther. 69:14-23
(2)  Mathijssen et al. (2002). J Natl Cancer Inst. 94:1247-1249
      Frye et al. (2004). Clin Pharmacol Ther. 76:323-329
7487
Version 8.0 02Mar2016 Page 68 of 71APPENDIX E
Drugs Associated with QTc Prolongation
The following table presents a list of drugs that prolong, may prolong or are unlikely to prolong the QTc.  This list 
is frequently updated.  For the most current list of medication s, refer to the following website: 
http://www.azcert.org/medical-pros/drug-lists/drug-lists.cfm .
Drugs that are generally 
accepted to have a risk of 
causing Torsades de PointesDrugs that in some reports have been 
associated with Torsades de Pointes 
and/or QTc prolongation but at this time 
lack substantial evidence for causing 
Torsades de PointesDrugs that, in some reports, have 
been weakly associated with 
Torsades de Pointes and/or QTc 
prolongation but that are unlikely to 
be a risk for Torsades de Pointes 
when used in usual recommended 
dosages and in subjects without 
other risk factors (e.g., concomitant 
QTc prolonging drugs, bradycardia, 
electrolyte disturbances, congenital 
long QTc syndrome, concomitant 
drugs that inhibit metabolism).
Generic/Brand Name Generic/Brand Name Generic/Brand Name
Amiodarone /Cordarone¬Æ Alfuzosin /Uroxatral¬Æ Amitriptyline /Elavi l¬Æ
Amiodarone /Pacerone¬Æ Amantadine /Symmetrel¬Æ Ciprofloxacin /Cipro ¬Æ
Arsenic trioxide /Trisenox¬Æ Atazanavir /Reyataz¬Æ Citalopram /Cele xa¬Æ
Astemizole /Hismanal¬Æ Azithromycin /Zithromax¬Æ Clomipramine /Anaf ranil¬Æ
Bepridil /Vascor¬Æ Chloral hydrate /Noctec¬Æ Desipramine /Pertofran e¬Æ
Chloroquine /Aralen¬Æ Clozapine /C lozaril¬Æ Diphenhydramine /Benadr yl¬Æ
Chlorpromazine /Thorazine¬Æ Dolasetron /Anzemet¬Æ Diphenhydramine / Nytol¬Æ
Cisapride /Propulsid¬Æ Dronedarone /Multaq¬Æ Doxepin /Sinequan¬Æ
Clarithromycin /Biaxin¬Æ Felbamate /Felbatrol¬Æ Fluconazole /Difluc an¬Æ
Disopyramide /Norpace¬Æ Flecainide /Tambocor¬Æ Fluoxetine /Sarafem¬Æ
Dofetilide /Tikosyn¬Æ Foscarnet /Foscavir¬Æ Fluoxetine /Prozac¬Æ
Domperidone /Motilium¬Æ Fosphenytoin /Cerebyx¬Æ Galantamine /Reminy l¬Æ
Droperidol /Inapsine¬Æ Gatifloxacin /Tequin¬Æ Imipramine /Norfranil¬Æ
Erythromycin /Erythrocin¬Æ Gemifloxacin /Factive¬Æ Itraconazole /Sp oranox¬Æ
Erythromycin /E.E.S.¬Æ Granisetron /Kytril¬Æ Ketoconazole /Nizoral¬Æ
Halofantrine /Halfan¬Æ Indapamide /Lozol¬Æ Mexiletine /Mexitil¬Æ
Haloperidol /Haldol¬Æ Isradipine /Dynacirc¬Æ Nortriptyline /Pamelor ¬Æ
Ibutilide /Corvert¬Æ Lapatinib /Tykerb¬Æ Paroxetine /Paxil¬Æ
Levomethadyl /Orlaam¬Æ Lapatinib /Tyverb¬Æ Protriptyline /Vivactil¬Æ
Mesoridazine /Serentil¬Æ Levofloxacin /Levaquin¬Æ Sertraline /Zolof t¬Æ
7487
Version 8.0 02Mar2016 Page 69 of 71Drugs that are generally 
accepted to have a risk of 
causing Torsades de PointesDrugs that in some reports have been 
associated with Torsades de Pointes 
and/or QTc prolongation but at this time 
lack substantial evidence for causing 
Torsades de PointesDrugs that, in some reports, have
been weakly associated with 
Torsades de Pointes and/or QTc 
prolongation but that are unlikely to 
be a risk for Torsades de Pointes 
when used in usual recommended 
dosages and in subjects without 
other risk factors (e.g., concomitant 
QTc prolonging drugs, bradycardia, 
electrolyte disturbances, congenital 
long QTc syndrome, concomitant 
drugs that inhibit metabolism).
Generic/Brand Name Generic/Brand Name Generic/Brand Name
Methadone /Dolophine¬Æ Lithium /Lithobid¬Æ Solifenacin /VESIcare¬Æ
Methadone /Methadose¬Æ Lithium /Eskalith¬Æ Trimethoprim-Sulfa /Sulfa¬Æ
Pentamidine /Pentam¬Æ Moexipril/HCTZ /Uniretic¬Æ Trimethoprim-Sulfa  /Bactrim¬Æ
Pentamidine /NebuPent¬Æ Moxifloxacin /Avelox¬Æ Trimipramine /Surmon til¬Æ
Pimozide /Orap¬Æ Nicardipine /Cardene¬Æ
Probucol /Lorelco¬Æ Nilotinib /Tasigna¬Æ
Procainamide /Pronestyl¬Æ Octreotide /Sandostatin¬Æ
Procainamide /Procan¬Æ Ofloxacin /Floxin¬Æ
Quinidine /Cardioquin¬Æ Ondansetron /Zofran¬Æ
Quinidine /Quinaglute¬Æ Oxytocin /Pitocin¬Æ
Sotalol /Betapace¬Æ Paliperidone /Invega¬Æ
Sparfloxacin /Zagam¬Æ Perflutren lipid microspheres /Definity¬Æ
Terfenadine /Seldane¬Æ Quetiapine /Seroquel¬Æ
Thioridazine /Mellaril¬Æ Ranolazine /Ranexa¬Æ
Risperidone /Risperdal¬Æ
Roxithromycin* /Rulide¬Æ
Sertindole /Serlect¬Æ
Sertindole /Serdolect¬Æ
Sunitinib /Sutent¬Æ
Tacrolimus /Prograf¬Æ
Tamoxifen /Nolvadex¬Æ
Telithromycin /Ketek¬Æ
Tizanidine /Zanaflex¬Æ
Vardenafil /Levitra¬Æ
Venlafaxine /Effexor¬Æ
Voriconazole /VFend¬Æ
Ziprasidone /Geodon¬Æ
7487
Version 8.0 02Mar2016 Page 70 of 71APPENDIX F
Blood Pressure ‚Äì Recommendations
for Data Collection/Recording and Event Management
Collection/Recording of B lood Pressure Information
1.0 General Guidelines
1.1          Frequency of monitoring. Blood pressure (BP) should  be monitored at least every 2 weeks for the duration of 
treatment.  More frequent monitoring should be considered on a study by study basis, particularly during the 
first two cycles of pazopanib therapy.
1.2          Data recording. All requ ired data should be recorde d in the appropriate CRF or on the subject‚Äôs blood pressure 
monitoring diary, as appropriate.  The following data are required at baseline and at each subsequ ent 
assessment :
xAssessment date and time
xPulse
xSystolic and diastolic BP (2 readings/assessment taken 5 minutes  apart while subject sitting)
1.3          Risk factors for hypertension (assess and record da ta in baseline history/physical CRF)
xDiabetes (type 1 or type 2)
xRenal disease (specify on CRF)
xEndocrine condition associated with HTN (specify on CRF)
xUse of steroids or NSAIDs (specify all concomitant meds)
xUnderlying cardiovascular condition ‚Äì specify ( i.e., ischemic heart disease)
2.0         Baseline data col lection (at study entry)
2.1 All subjects
xCurrent BP
xProteinuria, if present
2.2 Subjects with preexisting hypertension ( i.e., those for whom ‚Äúhypertension‚Äù is entered as a concomitant 
condition at study entry, or those who are currently receiving therapy with antihypertensive medication) ‚Äì also 
record:
xDate of HTN diagnosis (original)
xType HTN (essential or secondary)
xCTCAE grade of HTN (at time of study entry)
xTrade name, drug class*, dose, dose frequency, start/stop dates /ongoing of the following:
Antihypertensive agents taken at study entry
Antihypertensive agents taken in past ( e.g., discontinued for toxicity, lack of efficacy)
3.0         Follow up BP data collection (during study)
3.1 All subjects (at each clinic visit)
xCurrent BP
xProteinuria, if present
3.2 Subjects with treatment-emergent hypertension [defined as BP increase of >20 mmHg (diastolic) OR BP 
>150/100 (if previously within normal limits)] ‚Äì record at time of hypertension diagnosis and at all subsequent 
clinic visits:
xBP changes from baseline (or from previous assessment) (specify  CTCAE grade changes)
xHypertension-related symptoms as reported by subject ( e.g., headache)
xOther relevant changes associated with development of hypertens ion (e.g., ECG abnormalities)
xTrade name, drug class*, dose, dose frequency, start/stop dates/ongoing of currently prescribed 
antihypertensive agents
7487
Version 8.0 02Mar2016 Page 71 of 713.3 Subjects with preexisting hyp ertension at study entry ‚Äì record  at each clinic visit
xBP changes from previous clinic visit (specify CTCAE grade chan ges)
xHypertension-related symptoms reported by subject ( e.g., headache)
xOther relevant changes associated with development of hypertens ion (e.g., ECG abnormalities)
xChanges in antihypertensive medications since last assessment ( e.g., dose change, add/discontinue 
drug)
Classes of antihypertensive drugs include ACE inhibitors, calci um channel blockers, alpha block ers, beta blockers, diuretics, 
and angiotension II receptor antagonists.